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Abstract 
Colorectal cancer (CRC) is a leading cause of cancer related mortality in the Western 
World. Preto A and collaborators demonstrated that BRAF is crucial for proliferation and 
survival of microsatellite instability (MSI) CRC with BRAFV600E but not of MSI CRC 
harboring KRAS mutations. This provides evidence supporting BRAF as a good target for 
therapeutic intervention in patients with sporadic MSI CRC harboring activating 
mutations in BRAF. 
Gene therapy through siRNAs has been established as a new therapeutic alternative 
approach. Cationic liposomes have been extensively used among the nonviral methods 
used for gene delivery, being MO-based liposomes established as efficiently delivery 
systems for siRNAs. The  aim  of  this  thesis  was  to  develop  and  characterize  a novel 
DODAX:MO:DC-Chol based  system for specific delivery of BRAF-siRNA in CRC cells for 
intravenous or local administration. 
Our results demonstrated that all MO-based liposomal formulations were able to 
effiĐieŶtlǇ eŶĐapsulate si‘NA. We Đould oďtaiŶ staďle lipopleǆes of sŵall size ;ϭϬϬ−ϭϲϬ 
nm) with a positive surface charge (>38 mV). We showed that DODAC-based liposomes 
exhibited higher fusogenic ability but more cytotoxicity in the CRC derived cell line RKO. 
Post-pegylation of the liposomes and lipoplexes decreased efficiently the surface charge 
of liposomes, and post-pegylated liposomes revealed a better internalization in RKO 
cells compared with non-pegylated ones. All MO-based liposomes showed low 
hemolysis, which is suitable for an intravenous injection. The analysis of the transfection 
efficiency and BRAF silencing of the lipoplexes DODAB:MO:DC-Chol containing BRAF-
siRNA in RKO CRC cells, was not conclusive. Although further studies are needed, our 
preliminary results suggest that DODAB:MO:DC-Chol-BRAF-siRNA nanocarriers might be 
efficient in silencing BRAF expression in CRC cells. 
In conclusion, the DODAB:MO:DC-Chol lipoplexes developed in this work might be 
promising nanovectors  for siRNA delivery as a therapeutic approach for gene silencing 
in CRC. 
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Resumo 
O cancro colo-retal (CCR) é a principal causa de morte, por cancro, no mundo 
ocidental. Preto A e colaboradores, demonstraram que o BRAF é crucial para a 
proliferação e sobrevivência dos CCRs com instabilidadade de microssatelites (MSI) com 
BRAFV600E, mas não para os CCRs MSI com mutações do KRAS. Este facto fornece 
evidências que suportam o BRAF como um bom alvo para intervenção terapêutica em 
pacientes com CCR MSI esporádico com mutações do BRAF. 
A terapia genética através de siRNAs tem sido estabelecida como uma nova 
abordagem terapêutica alternativa. Os lipossomas catiónicos têm sido extensivamente 
usados entre os métodos não virais para a entrega de genes, sendo os lipossomas 
baseados em MO estabelecidos como eficiêntes sistemas de entrega de siRNAs. O 
objetivo desta tese foi desenvolver e caracterizar sistemas DODAX:MO:DC-Chol para 
entrega específica de BRAF-siRNA em células de CRC para administração intravenosa ou 
local. 
Os nossos resultados mostraram que todas as formulações de lipossomas baseadas 
em MO foram capazes de encapsular eficientemente siRNA. Obtivemos lipoplexos 
estáveis com pequenas dimensões (100-160 nm), com carga de superfície positiva (> 38 
mV). Nós mostramos que os lipossomas baseados em DODAC exibiram maior 
capacidade fusogénica mas mais citotoxicidade na linha celular RKO derivada do CCR. A 
pós-pegilação dos lipossomas e lipoplexos diminuiu de forma eficiente a carga da 
superfície dos lipossomas, e os lipossomas pós-peguilados revelaram uma melhor 
internalização quando comparados com os não-peguilados, em células RKO. Todos os 
lipossomas contendo MO demonstraram uma baixa hemólise, o que é adequado para 
uma injecção intravenosa. A análise da eficiência de transfecção e do silenciamento do 
BRAF pelos lipoplexos DODAB:MO:DC-Chol contendo BRAF-siRNA nas células RKO de 
CCR, não foi conclusiva. Apesar de serem precisos outros testes, os nossos resultados 
preliminares, sugerem que os lipoplexos de DODAB:MO:DC-Chol-BRAF-siRNA poderão 
ser eficientes no silenciamento da expressão do BRAF em células de CCR. Em conclusão, 
os lipoplexos DODAB:MO:DC-Chol desenvolvidos neste trabalho poderão ser 
nanovectores promissores  para entrega de siRNA, como uma abordagem terapêutica 
para o silenciamento de genes no CCR. 
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I. Introduction 
1. Nanomedicine: focus on cancer  
Nanotechnology has been revolutionizing the development of different branches of 
science since Feynman developed the vision of manipulating and controlling things on a 
small scale creating the fields of nanoscience and nanotechnology. The application of 
nanotechnology in medicine is termed as Nanomedicine. Nanomedicine provides 
significant opportunities and new perspectives for novel and effective treatments in 
many disorders. Nanomedicine can be defined as the design and development of 
nanotherapeutics and/or diagnostic agents at the nanoscale range (with diameters 
ranging from 1 nm to 1000 nm), that can be encapsulated within biological systems, to 
targeted delivery of biomedical entities for the prevention, diagnosis and treatment of 
many diseases1. 
 
Figure 1 Biomedical applications of nanotherapeutics 2. 
Cancer is a major public health problem all over the world. The incidence of cancer 
has been increasing in recent decades, and eradication of the major types of the disease 
remains an elusive clinical goal, largely due to the heterogeneous and idiosyncratic 
nature of individual cancers, and the inability to target therapeutics to neoplastic areas 
without damaging normal tissues3.  
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New perspectives for cancer treatment have been achieved using innovative 
nanomaterials for the development of new nanotherapeutics as drug delivery or gene 
therapy. 
2. Colorectal cancer: an overview 
Colorectal cancer (CRC) is a leading cause of cancer related mortality in the Western 
World being anticipated that 136,830 new cases in 2014 would be diagnosed and 
approximately 50,310 individuals will die of the disease (http://seer.cancer.gov/). 
CRC is characterized by a complex combination of epigenetic and genetic events. 
The sequence of genetic alterations inducing initiation and progression of the most CRCs 
are probably the best documented in the field of oncology4. Multiple studies have shown 
two major pathways in colorectal carcinogenesis, chromosomal instability (CIN) 
pathway (adenoma–carcinoma sequence) characterized by loss of alleles and 
microsatellite instability pathway (MSI). 
MSI involves alterations of tandem repeats of simple deoxyribonucleic acid (DNA) 
sequences (microsatellites). MSI has been associated with hereditary non polyposis 
colorectal cancer (HNPCC) syndrome and mutations in genes encoding DNA mismatch 
repair enzymes, such as MSH2, hMLH1, hPMS1, hPMS2 and hMSH6, which appear to be 
responsible for the development of MSI in CRC. Moreover, mutations in microsatellites 
of target genes such TGF-β ǁeƌe ideŶtified iŶ M“I tuŵoƌs, ǁhiĐh iŶ tuƌŶ, aƌe pƌesent in 
sporadic CRC. In sporadic CRC, MSI-High (MSI-H) is present in 10-20 % and MSI-Low in 5-
50 % of the cases. In about 80 % of MSI sporadic CRC are observed hipermethylation of 
hMLH1 promoter and are characterized by BRAF mutations5. Sporadic cases with MSI-H 
phenotype show different clinicopathological features compared with both MSS 
(microsatellite stable) and MSI-L, occurring predominantly close to colon and more 
frequently in female individuals. Histopathological features such mucinous or signet-ring 
cell differentiation and eǆĐess lǇŵphoĐǇte iŶﬁltƌatioŶs as ŵedullaƌǇ features 
characterize these cancers6. 
MSI-L e MSS tumors frequently hold KRAS and p53 mutations and loss of 
heterozygosity (LOH) at 5q, 19p and 18q. Nevertheless, literature is controversial about 
the real differences between MSI-L and MSS tumors. It has been described the 
possibility of MSI-l tumors development and progression associated with both MSI and 
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CIN pathways. Approximately 30-40 % MSI-H sporadic cancers have adenomatous 
polyposis coli (APC) mutations and 36 % MSI-H tumors have p53 mutations. Certain CRC 
develop associated with MSI and APC or with p53 mutations6,7. 
CRC can also be classified into epigenetic subgroups. DNA methylation of cytosine 
bases in CG rich sequences, also called CIMP (CpG Island Methylator Phenotype), is the 
most extensively studied deregulated epigenetic mechanism in colorectal cancer. CIMP 
have a certain overlap with MSI and CIN and their classification is based on a panel of 
methylation markers (CIMP high, intermediate and low). CIMP high appear to be 
associated with MSI and BRAF mutations and has a better prognosis while CIMP low 
appear to be associated only with KRAS mutations8.  
In general, several genetic alterations affect genes encoding signaling pathway 
proteins in cancer, including membrane receptors or cytoplasmic protein kinases and 
phosphatases. The discovery of a role for these pathways in the initiation and 
progression of CRC has progressively lead to the development of new therapies, aiming 
to target key effectors of these pathways in order to reduce tumor growth.  
2.1 Current colorectal cancer therapeutic 
Surgery and/or chemotherapy still represents the standard treatment regimen for 
CRC therapy. Chemotherapy is either used as adjuvant setting or in order to decrease 
the size of the metastases, providing an opportunity to perform surgery at a later stage9. 
Current therapeutic regimens rely primarily on the cytotoxic agents 5-fluorouracil (5-
FU), oxaliplatin and irinotecan, as well as the biologic agents targeting angiogenesis and 
the epidermal growth factor receptor (EGFR).  
3. Epidermal growth factor receptor as target therapy of colorectal 
cancer 
The EGFR and its downstream signaling pathways are involved in the development 
and progression of CRC, so both EGFR and some downstream components are 
appointed as targets for anticancer therapy. Two major signaling pathways activated by 
EGFR are the RAS-MAPK and PI3K-AKT pathway (Figure 2). 
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Figure 2. EGFR downstream signaling pathway. Adapted from SABiosciences.com. 
In the RAS-RAF-MEK-MAPK, an adaptor protein complex composed by the 
growth factor receptor-bound protein 2 adapter protein (Grb2), which harbors a 
tyrosine phosphate-docking site, a RAS GDP/GTP exchange factor, then activates the 
RAS GTPase. Activated K-ras recruits and activates the serine protein B-raf, and 
subsequent phosphorylation and activation of MEK and then MAPK occurs, resulting in 
activation of transcription factors in the cell nucleus. The MAPK pathway regulates the 
expression of a large number of proteins involved in the control of cell proliferation, 
differentiation and apoptosis. The other axis of the EGFR signaling cascade is the PI3K-
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AKT pathway, which results in cell growth, proliferation, and survival paralleling the RAS-
RAF-MEK-MAPK signaling pathway, so both pathways are closely related and have some 
overlap10. 
The first generation of approved targeted compounds for the treatment of 
metastatic CRC were the anti-EGFR monoclonal antibodies Cetuximab and 
Panitumumab. Cetuximab is a chimeric IgG1 and Panitumumab is a  human IgG2 
monoclonal antibody that binds selectively to the EGFR binding site, thus blocking 
ligand–receptor interaction and inhibiting downstream signaling11,12.  
Another currently approach was Bevacizumab, an anti-angiogenic recombinant 
humanized monoclonal antibody that inhibits vascular endothelial growth factor A 
(VEGF-A). Anti-angiogenic treatment also has been associated to tumor invasion in 
melanoma13, however, it remains unclear in case of colorectal cancer14.  
In the case of current EGFR-targeting antibodies, the lack of their efficiency is in part 
due to the fact that the tumor displays activating mutations of downstream oncogenes 
within the same pathway, namely the KRAS or BRAF genes.  
3.1 BRAF as a target for sporadic colorectal cancer 
BRAF is a key component of the RAS–RAF signaling pathway and a limiting step of 
several current therapies. BRAF mutation has been identified in a wide variety of human 
cancers, including sporadic CRC, melanomas and thyroid carcinomas15. Both BRAF and 
KRAS are prone to mutations in sporadic microsatellite unstable (MSI) CRC ( 31 – 45 and 
18 % of cases, respectively)16 and BRAFV600E mutation is inversely associated with 
oncogene KRAS17. BRAFV600E mutation promotes catalytic activity and is characterized by 
the substitution of thymidine by adenine at nucleotide 1799 leading to valine (V) 
substitution by glutamate (E) (referred to as V600E) at 600 codon in the activation 
segment18. BRAFV600E mutation is observed in 90 % of all BRAF mutations16. 
In sporadic CRC with a microsatellite instability (MSI) phenotype due to mismatch 
repair (MMR) deficiency, BRAF mutations were found in 31–45 % of the cases analyzed. 
In HNPCC tumors, BRAF mutations do not occur17. The association of BRAF with various 
cancers led to the investigation of BRAF pharmacological inhibitors and downstream 
proteins as therapies for individuals harboring BRAF-mutant tumors. 
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Sorafenib (Nexavar, or BAY 43-9006), was initially developed as a RAF inhibitor and 
tested for melanoma19. Recently, sorafenib was approved for the treatment of renal cell 
carcinoma and hepatocellular carcinoma, mainly because of its anti-angiogenesis effects 
rather than RAF inhibition20,21. Clinical responses to the highly selective small-molecule 
inhibitor of the BRAF (V600E) Vemurafenib and its analog PLX4720 differs widely, 
ranging from a response rate of approximately 80 % in melanoma to only 5 % in BRAF 
mutant CRC22-25. Other RAF inhibitors, such as  LGX818, XL281, ARQ-736, RAF 265, 
Dabrafenib, RO5212054 and GSK-2118436, are being actively evaluated in preclinical 
models and early clinical trials including26. In phase III of clinical trial there are 
combinations between multiple inhibitors as Dabrafenib plus Trametinib, Vemurafenib 
plus Dacarbazine and/or GDC-0973, Sorafenib plus multiple combinations, which are 
reviewed in Huang et al, 201326. 
Significant progress has been made in the development of RAF inhibitors, detection 
of common mutations, and understanding the role of these key signaling molecules in 
carcinogenesis. Multiple mechanisms have been suggested to support the clinical 
efficacy of BRAF. Interference on this pathway might achieve an anti-tumor effect, which 
is based in in vitro cell culture studies, xenograft tumor models, and clinical 
specimens27,28. Similarly to other cancer types, a survival plateau has been reached with 
combinations of cytotoxic drugs, increasing the demand for new approaches. 
Preto et al demonstrated that BRAF inhibition by RNA interference in colorectal 
cancer cell lines induces apoptosis selectively in cells harboring the BRAFV600E mutation 
(CO115 and RKO), not having any effect in cells with KRASG13D. BRAF down-regulation 
promoted a decrease in ERK1/2 phosphorylation and cyclin D1 expression levels in BRAF-
mutated cell lines in comparison to KRASG13D mutated cells. Upon BRAF inhibition, they 
also found an increase in p27Kip1 levels and a more pronounced decrease in the levels of 
anti-apoptotic protein Bcl-2, specifically in cell lines with BRAFV600E17. This report 
provides evidence supporting BRAF as a good target for therapeutic intervention in 
patients with sporadic MSI CRC harboring activating mutations in BRAF but not in 
KRAS17. 
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4. Gene therapy 
The prospect of somatic in vivo gene therapy as an alternative approach to 
conventional drugs has generated significant interest. There are approximately 50,000 
to 100,000 genes in the human genome and at least 30 % of colon cancers have been 
associated with defective genes, such as BRAF and KRAS genes. 
Gene therapy involves the delivery of genetic materials into cells. Gene therapy can 
be performed to replace or correct the malfunction of a gene, or to trigger an immune 
response or to produce a therapeutic substance. Gene therapy has come to encompass 
the delivery of several distinct nucleic acids, including plasmid DNA (pDNA), antisense 
oligonucleotides (ASOs) and RNA interference (RNAi)-based systems [including small 
interfering RNAs (siRNAs), short hairpin RNAs (shRNAs) and microRNAs (miRNAs)] to 
target cells. 
4.1 Gene therapy through RNA interference machinery 
RNAi is a fundamental pathway in eukaryotic cells by which sequence-specific siRNA 
targets and induce the silencing of complementary mRNA29,30. RNAi is triggered by the 
presence of long pieces of double stranded RNA, that are cleaved in the cytoplasm of 
the cells by the Dicer enzyme into fragments of about 22 nucleotides long known as 
siRNA31. This shortcut reduces the potential for an innate immune interferon response 
and turn off the cellular protein expression through interaction of long pieces of double-
stranded RNA with intracellular RNA receptor. 
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Figure 3. The mechanism of RNA interference (adapted from32). Long double-stranded RNA 
(dsRNA) is introduced into the cytoplasm, where it is cleaved into small interfering RNA (siRNA) 
by the enzyme Dicer. Also, siRNA can be introduced directly into the cell. The siRNA is then 
incorporated into the RNA-induced silencing complex (RISC), resulting in the cleavage of the 
sense strand of RNA by argonaute 2 (AGO2). The activated RISC–siRNA complex seeks out, binds 
to and degrades complementary mRNA leading to the target gene silence. The activated RISC–
siRNA complex can then be recycled for the destruction of identical mRNA targets. 
Chemically synthesized siRNA are double stranded RNAs (19-21 bp) with 2-
nucleotide single-stƌaŶded oǀeƌhaŶgs at theiƌ ϯ͛ eŶds that ŵiŵiĐ the Đleavage products 
of the enzyme Dicer33. Upon introduction into the cell cytoplasm, siRNA is incorporated 
into a protein complex know as RNA-induced silencing complex (RISC) that integrates a 
multifunctional protein, Argonaut 2, unwinds the siRNA after siRNA sense strand 
cleavage34. The activated RISC complex containing the antisense strand of the siRNA, 
locates and cleaves mRNA at position between nucleotides 10 and 11 on the 
complementary antisense stƌaŶd, ƌelatiǀe to the ϱ͛-end35. It then moves on to destroy 
additional mRNA targets preventing translation of the target mRNA into protein thus 
silencing the gene36.  
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The RNAi machinery can be exploited to silence nearly any target gene or multiple 
genes, giving it a broader therapeutically potential than any small-molecule drug32.  
Indeed, therapeutic gene expression silencing, through naked synthetic siRNA, has 
already been under clinical trials in various diseases (Table 1)33. 
4.1 The challenges of in vivo small interference RNA delivery 
As siRNA molecules are too large, hydrophilic and negatively charged to diffuse 
across the cell membranes and also require integration into the RNAi machinery, 
delivery material (vehicle) or chemical strategies are generally required to deliver 
therapeutic siRNA into the cell cytoplasm32,37.  
CoŵŵoŶ ĐheŵiĐal ŵodifiĐatioŶs iŶĐlude ƌeplaĐeŵeŶt of the Ϯʹ OH gƌoup of ƌiďose 
with -O-ŵethǇl oƌ Ϯʹ fluoƌogƌoups, iŶĐoƌpoƌatioŶ of loĐked oƌ unlocked nucleic acids and 
substitution of phosphorothioate linkages in place of phosphodiester bonds38. Despite 
the effectiveness shown by the chemical modified siRNA, to achieve an effective delivery 
it is necessary to avoid siRNA degradation and immune recognition, thus the most 
common approach is the siRNA encapsulation into delivery vectors. 
5. Properties of nanocarriers for delivery 
After more than 10 years of RNAi technology discovery, the fundamental challenge 
of siRNA therapy remains the development of safe and effective delivery vectors. In 
general, an ideal siRNA delivery system must resist in the extracellular milieu preventing 
nonspecific interaction with proteins or non-target cells, avoiding recognition of 
immune system, allowing extravasation in order to reach target tissues and promote cell 
internalization. 
5.1 Surface properties 
The interaction between nanoparticles with the target cell and various serum 
components in the body depends significantly on the surface charge of the delivery 
systems.  Firstly, positively charged nanoparticles promote the complex formation, 
called lipoplexes when cationic lipids are used, and compression of polyanionic nucleic 
acids of the siRNA through electrostatic interactions. Cationic systems can also promote 
internalization by adsorption to the negatively charged surface of the cells32. Several 
delivery systems rely on interactions with negatively charged serum proteins to allow 
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their uptake by target cells39. However, highly positive charged materials can induce 
nonspecific interactions  and  promote unfavorably aggregation40. Several approaches 
have been developed to increase nanovectors stability, including the incorporation of 
cholesterol and use of saturated lipids with higher transition temperatures41. Coating 
the delivery system with hydrophilic polymers (often polyethylene glycol (PEG)) avoids 
immune recognition42,43. PEG or other hydrophilic conjugates forms a barrier around 
nanoparticle controlling particle size, providing steric stabilization and protection from 
the physiological surroundings and allowing highest circulating half-lives, as well as 
reducing toxicity44. However, it has been reported that pegylation lowers the 
transfection efficiency (TE) of lipoplexes in different cell types45,46, decreasing cellular 
association and entrapment in the endosomal compartments being appointed as the 
motive for the reduction of the transfection efficiency47. PEG-ceramides constitute a 
viable alternative approach to regular PEG-lipids. Besides the exchangeability of the 
PEG-ceramides, also the post-pegylation step is required to obtain pegylated lipoplexes 
with a high gene transfer capacity. In a post-pegylation with PEG-ceramides, a smaller 
amount of PEG-lipid was sufficient to avoid aggregation of the lipoplexes in vitro, 
compared to the pre-pegylated lipoplexes. The shorter the acyl chain of the PEG-lipid, 
the easier is the transfer of the PEG-ceramides from the lipoplexes to the cell 
membrane48. 
5.2 Toxicity  
An effective and non-toxic siRNA delivery is the key challenge in delivery vehicles 
development. Both viral vectors and non-viral vectors are used for systemic delivery in 
clinical trials49. Particularly, 70% of gene therapy  clinical trials carried out so far have 
used modified viruses such as retrovirus, lentiviruses, adenoviruses and adeno-
associated viruses (AVVs)33. Despite of their high efficacy in gene therapy, viral vectors 
induce unacceptable levels of toxicity, such as carcinogenesis50, immunogenicity51, 
broad tropism52. In addition, difficulty in vector production  and DNA packaging capacity 
are limitations associated with viral gene therapy53.  Synthetic delivery vehicles, such as 
polymers and lipids, have been developed to offer alternatives to viral vectors for a non-
toxic and effective gene therapy.  
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6. Barriers to small interference RNA delivery in vivo 
6.1 Extracellular barriers 
Local siRNA delivery to the intestine is an attractive strategy due to the relative ease 
of access by oral, rectal or endoscopic administration. Systemic administration can also 
be a reliable approach to intestinal siRNA delivery.  
The successful of a local siRNA delivery is a significant challenge given the range of 
physiological and anatomical barriers associated with the gastrointestinal (GI) tract. 
Challenges to delivery of nucleic acids to the GI tract include the acidic environment of 
the stomach, components of intestinal fluids, intestinal and nuclease enzymes, presence 
of the mucus lining and the gut flora. In some conditions, the mucus layer can be 
reduced or missing in areas of acute inflammation, which can facilitate the access to the 
underlying epithelium. The inclusion of mucolytic agents prompted the delivery to 
target cells. Another barrier to intestinal delivery is the glycocalyx that is a size selective 
layer composed by glycoproteins and polysaccharides41. 
Systemic administration of synthetic delivery systems often results in accumulation 
in the organs of the reticuloendothelial system54. siRNA delivery particles larger than 
~20 nm avoid glomerular filtration barrier through the kidneys55. Delivery systems that 
are not eliminated by degradation, phagocytosis, or glomerular filtration can leave the 
bloodstream by crossing endothelium to reach target tissues.  
Some tumors present a combination of highly permeable endothelia and poor 
lymphatic drainage that can lead to increased accumulation of circulating nanoparticles 
in malignant tissue, a condition known as the enhanced permeation and retention effect 
(EPR)56. Moreover, it has been reported the success in targeting tumors through 
conjugation with ligands. The ligands used are known to bind to receptors that are 
overexpressed on the surface of the rapidly dividing cancer cells. For example, because 
of the high metabolic demands of rapid proliferation, many types of cancer cells 
overexpress transferrin and folate receptors, which makes conjugation with transferrin, 
folic acid or antibodies to these receptors, a successful targeting approach for 
engineered nanoparticles. Tumors targeting via folate-modified liposomes is an 
interesting, not so recent, approach since it is mediated by endocytosis which may 
contribute to bypass multidrug resistance. Daunorubicin  and  doxorubicin  liposomes  
have  been  specifically  delivered  to  tumor  cells  through  folate receptor targeting 
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resulting in enhanced cytotoxicity57,58.  Folate targeted vectors have been used for a 
specific delivery to tumors59. A recently international project, Nanofol, designed folate-
based nanobiodevices for integrated diagnosis/therapy targeting chronic inflammatory 
diseases (http://www.nanofol.eu/).  Nonetheless, as these receptors are expressed to 
some degree on many types of non-target cells, toxic off-target effects are not totally 
eliminated60-62. 
6.2 Cellular barriers to small interference RNA delivery  
Cell membrane blocks diffusion of complexes larger than ~1 KDa. Several endocytic 
mechanisms can be engaged to facilitate the internalization of the delivery vehicles. The 
internalization mechanism determines intracellular trafficking of the nanoparticles. This 
is a dynamic process, through which siRNA nanocarriers are transported to different 
subcellular destinations that can be shuttled to lysosomes, recycled back to the plasma 
membrane or delivered into other subcellular compartments. In the majority of cases, 
material targeted to the lysosomes for degradation increases osmotic pressure inside of 
the endosome, resulting in its swelling and subsequent escape of siRNA from the 
endosome63,64. Ligands conjugated to the surface of engineered nanoparticles can 
influence the mode of cellular internalization. Ligands such as folic acid, albumin and 
cholesterol have been shown to be uptaked through caveolin-mediated endocytosis, 
whereas ligands for glycoreceptors promote clathrin-mediated endocytosis63. It has 
recently been suggested that lipoplexes internalization pathways are cholesterol-
dependent and cholesterol affects their intracellular trafficking65,66. Engineered 
nanoparticles internalized through clathrin-mediated endocytosis are destined for the 
lysosomal compartment, whereas those internalized through a caveolin-mediated 
process are not. In clathrin-mediated endocytosis internalization, endosomal escape 
must occur before fusion with the lysosome to prevent degradation of the nanocarrier 
cargo under the harsh lysosomal conditions. Both caveolin and clathrin-mediated 
process requires endosomal escape to allow carrier access to the desired subcellular 
compartment, whether it is the cytosol, the mitochondria or the nucleus67. Alternatively, 
macropinocytosis can be engaged by incorporating cell-penetrating peptides, such as a 
trans-activating transcriptional activator (TaT) peptide into the design of engineered 
nanovectors68. The role(s) of particle size, shape and flexibility as well the ligand type, 
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density, multiplexing and region-specific labelling, in the internalization mechanism is 
yet to be better understood. 
Endosomal escape is considered the major limitation step for efficient gene 
transfection. Cationic lipids (CL) in lipid based nanoparticles (LNPs) interact with anionic 
lipids and proteoglicans of the endosome, causing destabilization of the endosomal 
membrane69. It has been hypothesized that the buffering capacity of nanoparticles 
activates a proton influx that raises osmotic pressure inside the endosome, resulting in 
its swelling and subsequent release of the siRNA to the cytosol64. Regardless of the 
release mechanism, some reports have shown that nucleic acids remain largely trapped 
inside the endosomes and lysosomes with only a small fraction being released to the 
cytoplasm. Several approaches have been attempted to promote endosomal escape 
through the incorporation of non-bilayer forming-lipids, such as DOPE, cholesterol 
and/or lipids with pH sensitivity such as DODAP and CHEMS70-72. Other strategy is the 
Incorporation of molecules, such as the peptide mellitin with membrane lytic activity 
which disrupts the endosomal membrane and the amino acid histidine with pH-
buffering capacity that bursts the membrane by increasing the endosomal osmotic 
pressure. The chemical drug chloroquine has also shown to promote nanocarrier 
endosomal escape through the phagolysosomal pH increase73,74. For many delivery 
systems, the precise mechanism of endosomal release is poorly understood as the exact 
intracellular trafficking pathways that affect delivery. Recently, Sahay and colleagues, 
reported that siRNA- based lipid delivery is substantially reduced as ~70% of the 
internalized siRNA undergoes endocytic recycling and exocytosis75. 
7. Non-viral lipid- based small interference RNA delivery  
Many non-viral delivery systems have been developed for siRNA-based therapy. 
siRNA vector delivery research has been influenced by experiences on intracellular DNA 
delivery despite of the significant differences between siRNA and DNA, which include 
the lowest overall size and charge of siRNA, and the intracellular trafficking in cytoplasm, 
in the case of siRNA, and to nucleus, in the case of DNA. Therapeutic siRNA delivery 
clinical trials includes the injection of siRNA alone or in combination with a range of 
synthetic delivery vectors, including lipids and liposomes, polymers and conjugate 
delivery systems (Table 1). 
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Table 1. Non-viral siRNA vectors under clinical evaluation (Adapted33). 
Delivery 
system 
Drug Sponsor Target 
Gene 
Disease Phase Status ClinicalTrials 
gov 
identifier 
Naked 
siRNA 
ALN-RSV01 Alnylam 
Pharma 
Nucleo-
capsid gene 
of RCV 
RSV infections II Completed NCT00658086 
 TD101 Pachyonychia 
Congenita 
Project 
KRT6A(N171
Kmutation) 
Pachyonychia 
congenita 
I Completed NCT00716014 
 AGN211745 Allergan FLT1 Age-related 
macular 
degeneration and 
choroidal 
II Terminated NCT00363714 
 QPI-1007 Pharma Optic 
Quark 
CASP2 Optic atrophy and 
non-arteric 
anterior ischemic 
optic neuropathy 
I Completed NCT01064505 
 I5NP Quark Pharma TP53 Kidney injury and 
acute renal failure 
I Completed NCT00554359 
    Delayed graft  
function and 
complications of 
kidney transplant 
I/II Active NCT00802347 
 PF-655 (PF-
04523655) 
Quark Pharma DDIT4 Choroidal 
neovascularization, 
diabetic 
retinopathy and 
diabetic macular 
edema 
II Completed NCT01445899 
    Age-related 
macular 
degeneration 
II Completed NCT00713518 
 Bevasiranib OPKO Health, 
Inc. 
VEGFA Diabetic macular 
edema 
II Completed NCT00306904 
    Macular 
degeneration 
II Completed NCT00259753 
 SYL1001 Sylentis S.A. TRPV1 Ocular pain and dry 
eye syndrome 
I/II Recruiting NCT01776658 
 SYL040012 Sylentis S.A. ASRB2 Ocular 
hypertension and 
open angle 
glaucoma 
II Completed NCT01739244 
 RXI-109 Rxi Pharma CTGF Cicatrix and scar 
prevention 
I Active NCT01780077 
    Hypertrophic scar II Recruiting NCT02030275 
    Keloid II Recruiting NCT02079168 
Lipid-
based 
ALN-VSP02 Alnylam 
Pharma 
KIF11 and 
VEGF 
Solid tumours I Completed NCT01158079 
 siRNA–EphA2–
DOPC 
MD Anderson 
Cancer Center 
EPHA2 Advanced cancers I Active NCT01591356 
 Atu027 Silence 
Therapeutics 
PKN3 Advanced solid 
cancers 
I/II Recruiting NCT01808638 
 TKM-080301 Tekmira 
Pharma 
Corporation 
PLK1 Cancer I/II Recruiting NCT01262235 
 TKM-100201 Tekmira 
Pharma 
Corporation 
VP24, VP35 
and Zaire 
Ebola L-
polymerase 
gene 
Ebola virus 
infection 
I Terminated NCT01518881 
 PRO-040201 Tekmira 
Pharma 
Corporation 
APOB Hypercholesterole
mia 
I Terminated NCT00927459 
 ALN-PCS02 Alnylam 
Pharma 
PCSK9 Hypercholesterole
mia 
I Completed NCT01437059 
 ALN-TTR02 Alnylam 
Pharma 
TTR TTR-mediated-
amyloidosis 
III Recruiting NCT01960348 
 ND-L02-s0201 Nitto Denko 
Corporation 
SERPINH1 Fibrosis I Completed NCT01858935 
CDP-
based 
CALAA-01 Calando 
Pharma 
RRM2 Solid tumours I Terminated NCT00689065 
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LOODER 
polymer 
siG12D LODER Silenseed Ltd. KRAS Pancreatic cancer II Active NCT01676259 
siRNA-
GaINAc 
conjugat
e 
ALN-TTRsc Alnylam 
Pharma 
TTR TTR-mediated 
amyloidosis 
I Recruting NTC01814839 
     II Recruting NTC01981837 
Dynamic-
Poly-
Conjugat
e 
ARC-520 Arrowhead 
Research 
Corporation 
Two 
conserved 
regions of 
Hbv 
transcrips 
Hepatitis B I Recruting NTC01872065 
     II Recruting NTC02065336 
ADRB2, adrenoceptor beta 2, surface; APOB, apolipoprotein B;CASP2, caspase 2, apoptosis-
related cysteine peptidase; CDP, cyclodextrin polymer; CTGF, connective tissue growth factor; 
DDIT4, DNA-damage-inducible transcript 4 (also known as RTP801);EPHA2, EPH receptor 
A2;FLT1, fms-related tyrosine kinase 1 (also known as VEGFR1); GalNAc, N-acetylgalactosamine; 
HBV, hepatitis B virus;KIF11, kinesin family member 11; KRT6A, keratin 6A; PCSK9, proprotein 
convertase subtilisin/kexin type 9; PKN3, protein kinase N3; PLK1, polo-like kinase 1; RRM2, 
ribonucleotide reductase M2; RSV, respiratory syncytial virus; SERPINH1, serpin peptidase 
inhibitor, clade H, member 1 (also known as HSP47); siRNA, small interfering RNA, TP53encodes 
p53; TRPV1, transient receptor potential cation channel, subfamily V, member 1; TTR, 
transthyretin;  
7.1 Lipid-based small interference RNA delivery 
Unillamelar and multilamellar liposomes are widely used as pharmaceutical delivery 
systems. In aqueous environment, lipid amphiphiles, chemical compounds including a 
hydrophilic region, a polar headgroup, covalently linked to the hydrophobic region of 
one or more nonpolar hydrocarbon chains are capable of self-assembly forming uni-or 
multilamellar lipid bylayer enclosing an hydrophilic core, which can houses the nucleic 
acid cargo76. Liposomes are categorized in small unillamelar vesicles (SUV), large 
unilamellar vesicles (LUV), giant unilamellar vesicles (GUV) and multilamellar vesicles 
(MLV) (Figure 4). 
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Figure 4. Schematic representation of basic structures and different types of liposomes. Small 
nillamelar vesicles (SUV), large unilamellar vesicles (LUV), giant unilamellar vesicles (GUV) and 
multilamellar vesicles (MLV). 
This process of self-assembly occurs above the critical vesicle concentration (CVC) 
and is dependent on parameters such as pressure, temperature, phospholipid 
headgroup repulsion and phospholipid tail length77. Liposomes can be created using 
single or multiple types of lipids, which allows for additional flexibility when optimizing 
the physical and chemical properties of the nanoparticle57. 
Liposomes have been used for the delivery of nucleic acids for over 20 years, since 
the studies performed by Felgner and colleagues describing the ability of the cationic 
lipid DOTMA (N-[1-(2,3-dioleyloxy)propyl]-N,N,Ntrimethlyl ammonium chloride) to 
deliver both DNA and RNA into mouse, rat and human cell lines78,79. Several lipid-based 
vectors have been used to deliver therapeutic nucleic acids to and /or via intestine in 
animal models. The majority of in vivo studies have used commercially available cationic 
lipids, such as Lipofectin®, Lipofectamine® 2000 and DOTAP. However, liposomes have 
poor stability in the intestine and this could explain why the cationic polymers of the 
polysaccharide chitosan are among the most widely used delivery vectors for intestinal 
gene therapy research41.  
Lipid based-siRNA delivery is the most widely used strategy in clinical trials among 
polymers or conjugates (Table 1)33. One class of lipid-based siRNA delivery systems 
under clinical evaluation is AtuPLEX, which consists of a cationic lipid (AtuFECT01), a 
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helper lipid (DPhyPE) and a PEG–lipid (PEG–DSPE) in a 50:49:1 ratio with siRNAs. This 
formulation was shown to internalize into mouse vascular endothelium after 
intravenous injection80. The AtuPLEX-based formulation Atu027 features a siRNA that 
targets the protein kinase N3 (PKN3) transcript and is under evaluation for the treatment 
of patients with advanced solid cancer (NCT01808638)81. Another approach, consisting 
in siRNA encapsulation into neutral liposomes composed of DOPC, was attempted with 
siRNA–EphA2–DOPC formulation (NCT01591356)82. This siRNA delivery system targets 
EPHA2 (which encodes a tyrosine kinase) and is being evaluated in patients with 
advanced cancers.  
Another class of lipid-based siRNA delivery systems under clinical evaluation are 
stable nucleic acid-lipid particles (SNALPs). SNALPs involve the encapsulation of nucleic 
acids into lipid-based nanoparticles (LNPs). The first SNALP formulation for siRNA 
delivery was reported in 2005 and targets the hepatitis B virus (HBV) in a mouse model 
for HBV replication83. Most SNALP targeted genes, in clinical trials, are disease-relevant 
targets in the liver because of theirs effectiveness in delivering nucleic acids into 
hepatocytes39. A second generation of SNALPs, ALN-TTR02 (Alnylam Pharmaceuticals), 
termed as Patisiran, features a DLinDMA analogue that has showed a tenfold increase 
in efficacy in preclinical studies, and is being evaluated for the treatment of 
transthyretin-mediated amyloidosis (ATTR) (NCT01960348)84. 
Several approaches have been developed to improve liposomes stability in different 
environments. In case of gene delivery through oral administration, some strategies as 
Nimos (nanoparticles in microsphere oral system) raised some interest. Nimos consists 
in a pDNA-based nanoparticle encapsulated within poly(epsilon-caprolactone) (PCL) 
microparticles. PCLs are degraded by intestinal lipases releasing the nanoparticles in the 
intestine and allowing them to be available for cell uptake85.  
8. Monoolein-based nanocarriers as promising vectors for small 
interference RNA delivery 
MO (Monolein) was first proposed as a helper lipid, for non-viral pDNA delivery, in 
a novel liposomal formulation with the  synthetic surfactant Dioctadecyl 
dimethylammonium bromide (DODAB)86. In this work, a liposomal formulation 
composed by DODAB and MO with different molar fractions was used to complex pDNA, 
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forming lipoplexes that effectively transfected Human Embryonic Kidney 293T cells, 
without inducing significant toxicity87,88. 
DODAB is a cationic lipid, firstly synthesized by Kunitake and Okahata in 199789, 
comprised by a quaternary ammonium headgroup (possessing one single positive 
charge) linked to a double acyl chain (C18:0) which  tends to form LUVs in excess of 
water. DODAB͛s phase ďehaǀioƌ has ďeeŶ eǆteŶsiǀelǇ studied aŶd its physicochemical 
characteristics are easily controlled, making it easy to design DODAB-based formulations 
with specific molecular structures. However, DODAB possesses a relatively high gel-to-
liquid crystalline phase transition temperature (Tm= 45 °C)90 that is superior to the 
huŵaŶ phǇsiologiĐal teŵpeƌatuƌe. Theƌefoƌe, DODAB͛s ďilaǇeƌ displaǇs a stƌoŶg ƌigiditǇ 
at normal body temperature limiting its use as a gene delivery system. MO is a natural-
occurring neutral surfactant, possessing a single unsaturated acyl chain (C 18:1) 
attached to a glycerol headgroup, that forms two inverted bicountinuous cubic phases 
(QIID and QIIG) in excess of water91. Similarly to the hexagonal structures, these cubic 
structures are also known to mediate membrane fusion processes92.  
 
Figure 5. Lipid phase diagrams of DODAB (A) and MO (B). Liquid-crystalline lamellar (Lα), inverted 
hexagonal (HII), inverted micellar (MII) and inverted bicontinous cubic (QIID and QIIG) 
(Diamond/Gyroid) phases. Adapted from91,93. 
The inclusion of a co-lipid with lower Tm, such as DOPE, cholesterol or MO, in the 
liposomal formulation, will lower the Tm of the lipid mixture, fluidiziŶg DODAB͛s bilayer. 
The aggregation behavior of concentrated DODAB/MO mixtures reveals the formation 
of the inverted nonlamellar phases, in excess of MO, and the prevalence of a lamellar 
organization for MO fractions below 50 % (Figure 6)94. 
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Figure 6. Cryo-TEM micrographs of DODAB:MO suspensions at χDODAB>0,5 (A) and χDODAB <0,5 (B, 
B1, B2, B3) at 25 oC. Scale bars: 200 nm (A,B) and 50 nm (B1, B2, B3). Adapted from94. 
The positively charged component of the liposomal formulation plays an important 
role in transfection efficiency of the delivery systems33,95. Despite the DODAB and 
dioctadecyldimethylammonium chloride (DODAC) molecules only differ in the 
counterion (Br- and Cl-), its effect on bilayer hydration significantly influences several 
properties, like the mean size and the gel to-liquid crystalline transition temperature96-
98. Recently, Oliveira et al,  2014, reported the efficiency of DODAX:MO (DODAB/C:MO) 
nanocarriers in siRNA delivery99. Varying the proportion of DODAX to MO and changing 
the counterion from Cl- to Br-, altered the nanocarriers properties in such a way that not 
only resulted in different levels of organization (Figure 7), but also in internalization and 
different transfection efficiencies which, in turn, resulted in different gene silencing 
capability.  
 
Figure 7. Schematic representation of siRNA- DODAX:MO (2:1) (A) and  siRNA- DODAX:MO (1:2) 
(B) lipoplexes structural model. Adapted from99. 
As described before for DODAB or MO rich domains, it was hypothesized that 
lamellar liposomes are prevalent in DODAX-enriched formulations (DODAX:MO (2:1)), 
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so then the encapsulation of siRNA would maintain the lamellar phase, and a 
multilamellar structure will predominantly be formed with anionic nucleic acids 
sandwiched between the lipid membranes. For MO-enriched formulations (DODAX:MO 
(1:2)), where a coexistence of lamellar and nonlamellar aggregates was observed, the 
encapsulation of siRNA will originate a DODAX lamellar phase enclosing the MO 
nonlamellar phases, where the siRNA will preferentially localize. The authors also 
suggested that endocytosis is the main internalization route for MO-based nanocarriers. 
In the case of siRNA delivery, DODAB:MO-based delivery system was more efficient then 
the DODAC:MO-based one, promoting lower cytotoxicity, higher internalization and 
gene silencing in H1299 eGFP cells99. 
The major disadvantage related with the use of cationic liposomes (CL)–
DNA/siRNA complexes (lipoplexes) is their low transfection efficiency. It has been 
reported that depending on the mode of cellular uptake, lipoplexes may be eliminated 
by lysosomal degradation or digestion, recycled back to the membrane, or delivered to 
other compartments. The use of cholesterol in the lipoplex formulation has been shown 
to enhance transfection both in vitro and in vivo100,101. Odete Gonçalves (2012), 
developed a DODAX:MO-based liposomal formulation including different contents of 
the catioŶiĐ Đholesteƌol ϯβ [N-;N͛,N͛- dimethylaminoethane)carbamoyl cholesterol (DC-
Chol). Depending on the preparation method, the increment of the DC-Chol has 
different effects on the transfection efficiency of MO-based lipoplexes but, in general 
terms, the presence of DC-Chol enhances the efficiency of pDNA delivery by the MO-
based nanocarriers102. 
Additional research, carried out by our group, demonstrated that pegylation of the 
lipoplexes makes them more stable, biocompatible and suitable for siRNA delivery 
(unpublished results). Moreover, the coating of the delivery systems with PEG-Folate 
resulted in higher cellular association in folate receptor positive MDA-MB-568 cells 
when compared to the cellular association observed in folate negative cell line MDA-
MB-435, with the nanocarriers including PEG-Folate. These results are an indicative of 
folate receptor-mediated internalization103. 
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9. Rationale and aims 
BRAF has been established by Preto et al, as a good target for individuals with 
sporadic MSI colorectal cancer harboring BRAFV600E, thus specific target inhibition of the 
BRAF protein could be a promising therapeutic approach for CRC. To the best of our 
knowledge, no BRAF specific drug has been developed. Gene therapy, through RNAi 
machinery, is a reliable alternative to the conventional cytotoxic drugs used currently in 
a combination regime in CRC treatment. The fundamental challenge of siRNA therapy 
remains the development of safe, effective and specific delivery vectors.  Cancer cells 
are known to overexpress folate receptor at the surface what constitute a good target 
for the development of specific nanoparticles. Attractive vehicles to deliver siRNA into 
target cells are the cationic liposomes because of the simplicity of their complexation 
with siRNAs, low toxicity and immunogenicity and superior pharmacokinetic properties 
and good transfection (especially if composition contains transfection enhancer like 
cholesterol). Elisabete Oliveira͛s gƌoup has established MO-based nanocarriers as 
promising nanocarriers for siRNA and DNA delivery. 
The aim of this thesis was to develop and characterize novel DODAX:MO-based 
systems incorporating DC-Chol, PEG-Ceramide and PEG-Folate for specificity, in order to 
avoid aggregation, immune recognition and increase the transfection efficiency, for 
specific delivery of BRAF-siRNA in colorectal cancer cells for intravenous or local 
administration. To achieve our goals we tested the produced nanoparticles in RKO cell 
line, which is a colorectal cancer cell line harboring a BRAFV600E mutation.  
Specifically in the project we aimed to: 
1- Study the physicochemical and biophysical characteristics of DODAX:MO:DC-
Chol nanocarriers. 
2- Perform preliminary studies of the nanocarriers for possible routes of 
administration, both local and intravenous administration. 
3- Validate biologically the DODAX:MO:DC-Chol nanocarriers, performing 
cytotoxic and cellular uptake assays. 
4- Evaluate BRAF expression silencing upon transfection with by DODAX:MO:DC-
Chol- BRAF siRNA nanocarriers. 
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II. Material and Methods 
1. Reagents 
The reagents dioctadecyldimethylammonium bromide (DODAB) and 
Ddioctadecyldimethylammonium chloride (DODAC) were purchased from Tokyo Kasei 
(Japan). 3ß-[N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol hydrochloride  (DC-
Chol), Poly(ethylene glycol)2000C(8)ceramide (PEG-cer), 1,2-Dioleoyl-sn-glycero-3-
phospho-L-serine (DOPS), 1,2-dioleoyl-sn-glycero-3-phosphatidylethanolamine-7-
nitrobenzofurazan (NBD-PEͿ ;ʄexc = ϰϲϱ Ŷŵ; ʄem = 535 nm) and 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine-N-(lissamine Rhodamine B sulfonyl) (Rhodamine-PEͿ ;ʄexc = 
ϱϲϬ Ŷŵ; ʄem = 583 nm) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). 
The Nucleopore Track-Etch Membranes were supplied from Whatman (Maidstone, UK). 
The 1-monooleoyl-rac-glycerol (MO), HEPES buffer, Trypsin, Sulforhodamine B sodium 
salt (SRB) and Thiazolyl Blue Tetrazolium Bromide (MTT) reagent were purchased from 
Sigma-Aldrich (Bornem, Belgium). RiboGreen reagent and Lipofectamine® 2000 were 
supplied from Invitrogen (UK). 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) was 
purchased from Corden Pharma (Liestal, Switzerland) and 1,2-dioleyl-3-
phosphatidylethanolamine (DOPE) was obtained from Lipoid GMBH (Ludwigshafen, 
Germany). Opti-MEM I Reduced Serum Medium and Fetal Bovine Serum (FBS) were 
purchased from Gibco (UK). The Dulbecco's Modified Eagle's Medium (DMEM), 
PeŶiĐilliŶ−stƌeptoŵǇĐiŶ ;ϱϬϬϬ IU/mL penicillin and 5000 ʅg/mL streptomycin) and 
HaŶk͛s BalaŶĐed “alt “olutioŶ ;HB““Ϳ ǁeƌe supplied ďǇ Bioǁest ;Nuaillé, France). 
TaqMan® Gene Assay HS01635040_S1, TaqMan® Universal Master Mix II, and TaqMan® 
MATP-6 and GAPDH endogenous control were supplied by Life Technologies (Carlsbad, 
CA, Estados Unidos). The SV Total RNA Isolation System was supplied by Promega 
(Madison, USA) and iScript cDNA synthesis kit was purchased by BioRad (Hercules, CA, 
USA). The mimicking colon fluid was gently assigned by biological engineering 
laboratory.  
A scramble siRNA sequence ;ϱ′GUCUCAAGUUUUCGGGAAGdTdTϯ′Ϳ was used in 
biophysical experiments, while, in transfections experiment, a siRNA sequence targeting 
human BRAF17 was used, ϱ͛-AAAGAAUUGGAUCUGGAUCAU-3´, both purchased by IDT 
(Leuven, Belgium). 
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2. Preparation of DODAX:MO:DC-Chol liposomes 
Cationic liposomes composed of DODAX:MO:DC-Chol liposomes (2:1:0; 5:4:1; 4:1:1) 
(mol:mol) (Table 2) were prepared by thin lipid film hydration method followed by 
extrusion, as published before99. Briefly, defined volumes from stock solutions of DODAB 
or DODAC, MO and DC-Chol in ethanol (20 mM) were placed in a round-bottomed flask, 
and the solvent was evaporated under vacuum (15 min at 50 °C) in a rotatory evaporator 
(VV Micro Rotary Evaporator, Heidolf). Subsequently, the lipid film was hydrated above 
the melting temperature of the cationic lipids (> 50 °C), with an appropriated volume of 
HEPES buffer (25 mM, pH 7.4) in order to obtain a 3 mM liposomal dispersion. In order 
to obtain a homogenous population of unilamellar vesicles, the liposomal dispersion was 
subjected to 5 extrusion cycles. During this process the liposomal dispersion was forced 
to pass, by compression with air, first through a filter with a pore size of 400 nm (first 
cycle) and then four times through a 100 nm pore sized filter (Track-Etched Membranes 
(Nuclepore)). To increase the fluidity and facilitate the extrusion, the extruder (Lipex 
Extruder (Northern Lipids)) was pre-heated at 60 °C. 
For the biological assays, liposomes were additionally sterilized using a membrane 
filter with a pore of 200 nm (Filtropur S 0.2 (Sarstedt)). 
DODAX:MO:DC-Chol liposomes were post-pegylated by the addition of 10 % of 
PEG-ceramide (chain 8) (mol:mol) to the liposomal dispersion, followed by 1 h of 
incubation at 55 °C. The formulations were left to stabilize at least 20 min at room 
temperature before use104.  
Table 2 Lipid Molar fraction (χ) of the liposomal formulations 
 ΧDODAX ΧMO ΧDC-CHOL 
2:1:0 0.67 0.33 - 
4:1:1 0.68 0.16 0.16 
5:4:1 0.50 0.40 0.10 
 
3. Lipid mixing/Fusion assay 
Förster Resonance Energy Transfer (FRET) is a non-radiative transfer of energy 
between an excited donor and appropriate acceptor chromophore, mediated by long-
 24 
 
range dipole-dipole interactions (Förster). The energy transfer requires a spectral 
overlap between the donor emission and acceptor absorption spectra and a minimal 
distance between the donor and the acceptor (lower than 10 nm). Also, the energy 
transfer depends on the donor and acceptor fluorescence quantum yields and the 
relative orientation of their transition dipole moments105. The energy transfer efficiency 
(ϕFRET) between donor and acceptor can be an indication of lipid mixing/fusion 
occurrence. Lipid probes like NBD-PE and Rho-DOPE can be used to monitor the process 
of lipid mixing/fusion between liposomes106. For instance, endosomes models labeled 
with these two probes can be mixed with DODAX:MO:DC-Chol liposomes, and the FRET 
efficiency can be determined in order to evaluate the lipid mixing/fusion processes 
between them. 
In case of fusion or lipid mixing, an increase of the average distance between the 
donor and acceptor chromophores will occur, resulting in an increase of the average 
donor signal and in a loss of the acceptor signal, consequently decreasing the ϕFRET. A 
representation of FRET dynamics using this donor/acceptor fluorescent pair is shown in 
Figure 8.  
 
Figure 8. Theoretical model for the lipid mixing between DODAX:MO:DC-Chol and NDB-PE and 
Rhodamine-PE labeled endosomes models (A) and the resulting variation in donor and acceptor 
emission spectra (B). 
Labeled liposomes composed by PC:PE:PS:Cholesterol (5:1:1:2) (mol:mol) were 
used as model endosomes and prepared by ethanol injection as described elsewhere87. 
The double-labeled Donor/Acceptor (DA) model endosomes included 1 % mol of NBD-
PE and 2 % mol of Rho-PE, and single-labeled Donor (D) liposomes included only 1 % 
NBD-PE. The lipids were mixed and injected, drop by drop, in pre-warmed MES-HEPES 
buffer (20 mM, pH 7.2 and/or pH 5.5) under strong vortex stirring and let to stabilize at 
room temperature. The pH 7.2 and/or pH 5.5 were used in order to mimic early and late 
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endosomes model. To perform the fusion assay, 50 µM of the (DA) or (D) early or late 
endosomes model, and 50 µM of the DODAX:MO:DC-Chol liposomes were mixed and 
the final volume was raised to 2.5 mL with MES-HEPES buffer (pH 5.5 or 7.2). The 
ﬂuorescence emission spectra (480 - 700 nm) was recorded in a Luminescence 
Spectrometer LS 50 (Perkin-Elmer) using a ʄexc = 460 nm, with spectral bandwidths of 1 
nm. The steady-state ϕ FRET of the liposomes containing both donor and acceptor 
fluorophors as determined according to following equation:  
Equation 1. ϕ FRET equation �ி�ா� ሺ%ሻ = ܨ஽ − ܨ஽஺ܨ஽ ×  ͳͲͲ 
where FD is fluorescence intensity of the single-labeled liposomes and FDA is fluorescence 
intensity of the double-labeled liposomes at ʄem = 530 nm. FRET was quantified as a 
function of time after addition of DODAX:MO:DC-Chol liposomes to the (D) and (DA) 
endosomes model. 
4. Preparation of siRNA-based DODAX:MO:DC-Chol lipoplexes 
siRNA-lipoplexes were prepared by incubating 100 µL of siRNA solution (4 µM) in 
HEPES buffer (25 mM, pH 7.4) with appropriated volumes, in order to obtain the desired 
charge ratios, of DODAX:MO:DC-Chol liposomes (1 mM), prepared according to section 
3. After vortex stirring, the lipoplexes were left 20 min at room temperature. The 
balance between charges is given by the charge ratio (+/-). 
Equation 2. Charge ratio calculation ܥ. �. ሺ+ ∕ −ሻ = [+][−] = [�݉݉݋݊�ݑ݉ ݃ݎ݋ݑ݌ݏ ݋݂ ܦܱܦ�� + �݉�݊݁ ݃ݎ݋ݑ݌ݏ ݋݂ ܦܥ − ܥℎ݋݈][ܲℎ݋ݏ݌ℎܽݐ݁ ݃ݎ݋ݑ݌ݏ ݂ݎ݋݉ ݏ��ܰ�]  
The positive charges are given by the concentration of ammonium groups present in 
DODAX lipids and by the amine present in DC-Chol, where the negative charges are given 
by the number of phosphate groups in siRNA, which is directly correlated with the 
nucleotide concentration.  
Post-pegylated siRNA-lipoplexes were prepared through the addition of 10 % of 
PEG-ceramide (chain 8) to the cationic lipid presented in solution (mol:mol), followed by 
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1 h of incubation at 55 °C as described before. The formulations were let to stabilize at 
least 20 min at room temperature before use. 
5. RyboGreen assay 
Non-pegylated siRNA-DODAX:MO:DC-Cholesterol lipoplexes were prepared at 
charge ratios (+/-) 1, 3, 5, 7, 10 and 15, as described above. Efficiency of siRNA 
encapsulation was characterized by RiboGreen assay. RiboGreen is a RNA intercalating 
fluorescence probe used to quantify RNA in solution.  
The RiboGreen assay was performed according manufaĐtuƌeƌ speĐifiĐatioŶs: ϭϬϬ ʅL 
of lipoplexes, HEPES buffer (25 mM, pH 7.4) as blanck, and siRNA (0.4 µM) (the 
concentration of siRNA in diluted lipoplexes) were plated in a dark 96 well plate (NUNC, 
Denmark). Then, ϭϬϬ ʅL of RiboGreen (200x) was added to each condition and incubated 
for 5 min in the dark. The fluorescence was measured in a Fluoroskan ACEN FL 
Microplate Fluorometer and Luminometer (Thermo scientific), using the 
excitation/emission filter pair of 485/538 nm. The RiboGreen solution was prepared by 
200x fold dilution of the RiboGreen stock solution (750 mM) in a Tris-EDTA buffer (10 
mM Tris-HCl, 1 mM EDTA, pH 7.5) (200x) diluted from the stock solution with ultrapure 
water RNase free. All procedure was carried on ice and using RNAse free material.  
6. Size and Zeta-potential measurements 
7.1 Dynamic light scattering (DLS) assay 
Dynamic light scattering, or photon correlation spectroscopy technique, is based on 
thermally induced particles collisions with the solvent molecules, resulting in the 
spontaneous diffusion towards a homogeneous distribution on solvent, known as 
Brownian motion. The particle movement is inversely proportional to particle size: the 
smaller the particles are, the more rapidly they move, as portrayed in stokes-Einstein 
equation. 
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Equation 3. Stokes-Einstein Equation ܦ =  ݇஻�6�ߟ�� 
where (D) is the diffusion coefficient of the particle, (kB) the Boltzmann constant (1.38 x 
10-23 m2kg s-2K-1), (T) the temperature, (ɻ) the dynamic viscosity of the dispersion 
medium and (RH ) is the hydrodynamic radius of the particle.  
The intensity of the detected scattered light fluctuates over time (t) at a rate that is 
particle size dependent. The parameters obtained through cumulative analysis, are the 
Z-average size and the of polydispersity index (PdI), according to equation: 
Equation 4. Polynomial fit to the log of the of the scattered light fluctuation in time. ܮ݊ ሺܩͳሻ = ܽ + ܾݐ + ܿݐ2 + ݀ݐ4 + ݁ݐ4+… 
The parameter b is known as the z-average diffusion coefficient, and is converted to size 
using the dispersant viscosity, and some other instrumental constants, and the 
polydispersity index (2c/b2). The z-average parameter is only reliable when PdI is lower 
than 0.1, above this, z-average can only be used for comparisons purposes (Malvern 
2004). When the size distribution is very broad, the polydispersity will be too high (> 0.5) 
and the calculated z-average value will be unreliable. In this case, the distribution 
analysis should be used instead of the z-average value107. 
For size measurements, DODAX:MO:DC-Chol liposome were diluted in HEPES buffer 
(25 mM, pH 7.4) to a final volume of 1 mL and final lipid concentration of 1 mM. 
Measurements were performed in disposable polystyrene cuvettes (Sarstedt, 
Germany), at 25 °C, in a Malvern ZetaSizer Nano ZS particle analyzer (Malvern 
Instruments, UK). 
Total complexation between liposomes and siRNA occurs when the efficiency of 
siRNA encapsulation is similar to 100 %, and hydrodynamic radius of the lipoplexes is 
similar to the liposomes. Therefore, non-pegylated and post-pegylated lipoplexes, 
prepared at charge ratio 7, were also characterized by dynamic light scattering using a 
similar processing protocol used for the liposomes processing. 
7.2 Electrophoretic light scattering (Zeta (ζ-) potential) assay 
Electrophoretic light scattering is a quasi-elastic light scattering technique that 
measures the surface charge of particles in a solvent, through the ɺ- potential. Charged 
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colloidal particles are characterized by two layers around their surface that result from 
attracted counter-ions: a Stern layer formed by counter-ions firmly attached, and an 
external diffuse layer characterized by a dynamic equilibrium between positive and 
negative ions, being either attracted or repelled by the Stern layer or other ions. 
 
Figure 9. Schematic representation of the electrical double layer surrounding a particle in 
suspension, with the correspondent potential to each component of the layer107.  
Zeta potential is the electric potential resulting from the electrical double layer, and 
can be measured through an electrical field application. When an electric field of know 
strength is applied to particle dispersion, it produces a particle movement known as 
electrophoretic mobility. The relation between the electrophoretic mobility (µ) of a 
particle and its corresponding zeta potential (ɺͿ is giǀeŶ ďǇ the HeŶƌǇ͛s eƋuatioŶ. 
Equation 5. HeŶƌy’s EƋuatioŶ � = ߝ௥ߝ0ߞߟ  �݂ሺܭܽሻ 
where (εͿ is the dielectric constant of the dispersion medium, (ɻ) the viscosity of the 
dispersion medium, and fH;kaͿ is the HeŶƌǇ͛s fuŶĐtioŶ that Đoƌƌelates the ƌatio of the 
paƌtiĐles ƌadius to the douďle laǇeƌ thiĐkŶess. ɺ-potential measurements also provide 
information about the stability of the particle dispersion: high zeta potential values 
(superior to +30 or inferior to -30 mV) mean that electrostatic repulsions overcome the 
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Van der Wall interactions, thus preventing particle aggregation. Oppositely, neutral zeta 
potential values can contribute for particle aggregation108. 
For ɺ-potential measurements, DODAX:MO:DC-Chol liposomes and lipoplexes, were 
processed in a similar way as for size measurements, however, using folded capillary 
cells (Malvern). Measurements were performed in (Sarstedt, Germany), at 25 °C, in a 
Malvern ZetaSizer Nano ZS particle analyzer (Malvern Instruments, UK). 
Total complexation between liposomes and siRNA occurs when the efficiency of 
siRNA encapsulation is similar to 100 %, whereas the lipoplexes charge surface is similar 
to liposomes. Therefore, the ɺ -potential of lipoplexes and post-pegylated lipoplexes, 
prepared at charge ratio (+/-) 7, were evaluated. 
7. Cell lines and culture conditions 
The RKO cell line is a poorly differentiated colorectal cancer cell line harboring a 
BRAFV600E mutation109.The cell line was grown in DMEM supplemented with 10 % (v/v) 
of heat-inactivated FBS and 1 % (v/v) of an antibiotic/antimycotic 
(PeŶiĐilliŶ−stƌeptoŵǇĐiŶ) solution. RKO cell line was maintained at 37 °C and 5 % CO2 in 
a humidified incubator and routinely passaged every 3 or 4 days using 0.05 % Trypsin-
EDTA solution in order to maintain subconfluency. 
8. Hemolysis assay 
Hemocompatible nanocarriers can be defined as nanoparticles which do not induce 
any form of toxicity and remain efficacious after being exposed to blood. Hemolysis 
assays are one of the regularly conducted tests when evaluating the hemocompatibility 
of new nanoformulations. 
The hemolytic activity of liposomes was investigated using an established method 
based on the release of hemoglobin from damaged erythrocytes. Briefly, erythrocytes 
were isolated from 5 mL of fresh blood by centrifugation (600 g, 10 min). The 
erythrocytes were washed in PBS until the supernatant was clear and colorless and then 
diluted to the original volume of 5 mL. 150 µL aliquots of the erythrocyte suspension 
were incubated with 150 µL of DODAX:MO:DC-Chol liposomes for 30 min at 37 °C in a 
water bath, as described elsewhere110. For this experiment, liposomes were diluted in 
pure PBS buffer (pH 7.4) and added in order to achieve final concentrations of 5, 25 and 
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50 µg/mL in 300 µL of total volume. After a centrifugation at 600 g for 10 min, to pellet 
the erythrocytes, the hemoglobin concentration in the supernatant was quantified 
measuring the absorbance at 541 nm, using a SpectraMax Plus 384 absorbance Plate 
Reader (Molecular Devices). A 2 % triton X-100 solution and H2O were used as the 
positive control and PBS buffer (pH 7.4) as negative control. PBS was used as blank. 
The percentage of hemolysis was quantified using the following equation: 
Equation 6. Hemolysis Equation % ܪ݁݉݋݈�ݏ�ݏ =  �ܾݏ௦௔௠௣௟௘ − �ܾݏ௕௟௔௡௞�ܾݏ௣௢௦�௧��௘ ௖௢௡௧௥௢௟ − �ܾݏ௕௟௔௡௞ 
 
9. Cytotoxic assays 
The cytotoxicity of the pegylated and non-pegylated DODAX:MO:DC-Chol liposomes 
was assessed in the RKO cell line by MTT and sulforhodamine B assays. 
Briefly, after reaching the exponential phase of growth, RKO cells were seeded at 
7500 cells per well, in 96 well plates (TPP, Switzerland) and left 12-24 h, for adhesion, in 
an atmosphere of 5 % CO2 and at 37 °C. After cell culture medium removal, the cells 
were incubated with non-pegylated and pegylated liposomes, diluted in DME medium 
to final conceŶtƌatioŶs of ϱ, Ϯϱ aŶd ϱϬ ʅg/mL. DMEM medium was used as a viability 
control and DMSO at 30 % (v/v) as a cell death control. Additionally, an appropriated 
quantity of HEPES buffer (25 mM, pH 7.4) was used as a control mimicking the higher 
quantity of liposome added and a blank control of solvent. The cells were maintained in 
proper culture conditions for 48 hours, at 37 °C with 5 % CO2 and then subjected to 
cytotoxicity assays. 
10.1 MTT assay 
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay is 
based on the conversion of MTT into formazan crystals by metabolically active cells. This 
tetrazolium salt is metabolized by mitochondrial enzymes, resulting in a colorimetric 
product that can be quantified by absorption at 570 nm. In case of metabolism failure, 
the formazan crystals will be blocked resulting in a decrease on absorption light. The 
assay determines the total mitochondrial activity, a measurement of metabolic activity 
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that is related to the number of viable cells111. MTT assay is widely used to measure the 
in vitro cytotoxic effects. The cytotoxicity of the liposomes was assessed in the RKO cell 
line by the MTT assay, after 48 h incubation 
Briefly, after incubation peƌiod, ϭϬ ʅL of a MTT stock solutioŶ ;ϱ ʅg/mL in PBS 1x) 
was added to the cells, followed by a period of 4 h of incubation, in humidified incubator 
(37 °C, 5 % CO2). Finally, 110 µL of a solubilization solution, composed by isopropanol 
with 1 % of HCl (37 %) and 10 % of Triton X-100, was added to each well and the 
formazan crystal were dissolved by resuspension with the multi-channel pipette. The 
absorbance was measured at 570 nm in a SpectraMax Plus 384 absorbance Plate Reader 
(Molecular Devices) using the appropriated software (SOFT Max Pro) protocol, and the 
absorbance at 690 nm was also determined as a reference value.  
10.2 Sulforhodamine B colorimetric assay 
Sulforhodamine B (SRB) assay is a colorimetric experiment based on protein 
staining. The SRB dye binds to basic amino acids of cellular proteins and then 
colorimetric evaluation provides an estimate of total protein mass which is related to 
cell number, consequently a measure of cytotoxicity112. 
After an incubation period, the cell culture medium was removed, the cells were 
washed with PBS 1x, and 250 µL of 1 % acid acetic in methanol (100 %) solution was 
added to the wells. The plates were incubated at -20 °C for 1 h and 30 min and then left 
to dry in an incubator at 37 °C for 15 min. Afterwards, 50 µL 0.5 % Sulforhodamine B (in 
1 % acid acetic) was added to each well, and the plates were incubated for 1 h and 30 
min at 37 °C in the dark. In order to remove the unbound SRB, the wells were washed 
with 1 % acid acetic solution, and left to dry at 37 °C for 10-15 min. Finally, 100 µL of Tris 
10 mM was used to dissolve SRB, and the absorbance was read at 540 nm in SpectraMax 
Plus 384 absorbance Plate Reader (Molecular Devices) using the appropriated software 
(SOFT Max Pro) protocol. 
10. Cellular uptake assay  
In cellular uptake experiment, liposomal formulations were prepared, with 2 mol % 
of NBD-PE, by the film hydration method followed by extrusion and post-pegylation. 
After reaching the exponential phase of growth, RKO cells were seeded at a density of 
3.2 x104 cells per well in 24 well plates (TPP, Switzerland). After 30 min of incubation at 
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4 °C, the cells were washed two times with PBS 1x, treated with 25 and 50 µg/mL of the 
liposomal formulations (diluted in HBSS) and incubated for 6 h at 37 °C, 5 % CO2. Then, 
the extracellular medium was aspirated and the cells were washed with cold PBS 1x in 
order to remove extracellular fluorescence residues. The cells were finally lysed with 
ϱϬϬ ʅL of Triton X -100 (5 % Triton X-100 in PBS) and collected for fluorescence 
measurements. The internalized lipid concentration was inferred from calibration 
curves, obtained performing appropriated dilutions of the liposomal dispersions in 
Triton X -100 (5 % Triton X-100 in PBS). The fluorescence measurements were performed 
in a SynergyMx with Gen5TM software (Bio-Tek Instruments, Inc., EUA), using the 
excitation/emission filter pair of 580/530 nm. A 1 % triton X-100 solution and H2O were 
used as the positive control and PBS buffer (pH 7.4) as negative control. 
11. BRAF silencing by RNA interference using nanocarriers 
12.1 Transfection of BRAF small interference RNA  
RKO cells were transfected 24 h after seeding at 6.2 x 104 in 12-well plates (final 
volume of 1 mL/well). Cells were washed with PBS 1x and incubated with 750 ʅL of Opti-
MEM (Reduced serum medium). Pegylated and non-pegylated DODAB:MO:DC-Chol 
lipoplexes (5:4:1; 4:1:1) were prepared according with section 4. 250 µL of 100 nM of 
the lipoplex (DODAB-based lipoplexes and pegylated DODAB-based lipoplexes) diluted 
in Opti-MEM (final volume 1 mL/well) were added to each well. Control cells were 
transfected with 3 µL lipofectamine® 2000 and 100 nM of BRAF siRNA, according to the 
manufacturer instructions. Briefly, 3 µL lipofectamine 2000 (Invitrogen) was diluted in 
Opti-MEM at a fiŶal ǀoluŵe of ϭϮϱ ʅL (Mix I) and incubated 5 min at room temperature 
(RT). Then, 5 µL of BRAF were diluted in Opti-MEM at a final volume of 125 ʅL (Mix II). 
Mix I and II were gently combined, followed by an incubation period of 20 min at RT and 
then added to control well. Cells were incubated for 14 h at 37 °C, then the medium 
growth was refreshed and the cells were incubated for 48 h at 37 °C. All procedures were 
performed under RNAse free conditions and forward transfection was used. 
12. Quantitative Polymerase Chain Reaction assay 
Quantitative Chain Reaction (qPCR) assay is based in polymerase chain reaction 
which is used to amplify and allows precise quantification of specific nucleic acids in a 
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complex mixture by fluorescent detection of labeled PCR products. Detection can be 
accomplished using specific as well as nonspecific fluorescent probes. qPCR is often used 
in the quantification of gene expression levels as it is the most sensitive technique. BRAF-
siRNA silencing of DODAB:MO:DC-Chol (5:4:1; 4:1:1) was evaluated by qPCR. 
RNA extraction was performed using SV Total RNA Isolation System (Promega) 
according manufactures protocol. Briefly, 175 µL RNA Lysis Buffer (RLA) (+ BME) was 
added at each well and transferred for microtubes. After, 350 µL RNA Dilution Buffer 
(RDA, blue) were added to each condition and mixed by inverting 3–4 times. After 
heating the sample at 70 °C for 3 min, they were centrifuge for 10 min at 14 000 g and 
the cleared lysates were transferred to fresh tubes. 200 µL of 95% ethanol were added 
to cleared lysate and mixed well. The solutions were transferred to Spin Basket Assembly 
and centrifuged for 1 min (14 000 g). After discard eluate, 600 µL of RNA Wash Solution 
(RWA) (+ ethanol) were added and the solution were centrifuged for 1 min (14 000 g) 
and the eluate were discard again. 50 µL of DNase mix (for preparation: 40 µL of Yellow 
Core Buffer; MnCl2, 5 µL of 0.09 M; 5 µL of DNase I) were added to the membrane of the 
Spin Basket Assembly and incubated at RT for 15 minutes. The reaction was stopped by 
adding of 200 µL of DNase Stop Solution (DSA) (+ ethanol) being subjected to a 
centrifugation for 1 min (14 000 g). The membrane was washed by adding, firstly 600 µL 
and after 250 µL of RNA Wash Solution (RWA), centrifuged for 1 min and 2 min at 14 000 
g, respectively. To elute RNA, 35 µL of Nuclease-Free Water were added to the 
membranes and centrifuged for 1 min and stored at - 80 °C. The successful of cDNA 
synthesis depends on RNA purity, quality and quantity (< 1 µg). 
In order to evaluate extracted RNA, the quantification by absorbance was 
performed in a NanoDrop 1000 Spectrophotometer (Thermo Scientific). The absorbance 
ǁas ƌead at ʄ ϮϲϬ ;AϮϲϬͿ aŶd ϮϴϬ ;AϮϴϬͿ aŶd eǆpƌessed as a ƌatio ;AϮϲϬ/AϮϴϬͿ ǁhiĐh 
was used as quality reference that should be between 1.8 and 2.2. Quality control was 
also verified usiŶg aďsoƌďaŶĐe ŵeasuƌed at ʄ=230. 
In order to synthetize cDNA from extracted RNA, iScript cDNA synthesis kit 
(BioRad) was used. To perform the cDNA synthesis, RNA template at maximum 1 µg is 
diluted in nuclease-free water in a final volume of 15 µL. Firstly, were added the 
nuclease-free water, followed by the addition of 4 µL of 5x iScript reaction mix and the 
determined volume of RNA template, finally 1 µL of iScript reverse transcriptase was 
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added in a 20 µL of total volume per reaction. All procedure were carried on ice and with 
RNAse-free tips. The conversion to cDNA was performed in a CFXϵϲ TouĐh™ qPCR 
Detection System (BioRad) were carried the following reaction protocol: 5 min at 25 °C, 
60 min at 42 °C, 5 min at 85 °C and held at 4 °C. The cDNA storage was performed at -20 
°C.  
The PCR reaction mix was proceed by adding 1 µL of 20X TaqMan Gene 
Expression Assay (BRAF or MT-ATP6) (Applied Biossystems), 10 µL 2X TaqMan Gene 
Expression Master Mix (Applied Biossystems), 1 µL cDNA template and 8 µL RNAse free 
water (volume for 20 µL per reaction). The qPCR was coŶduĐted iŶ CFXϵϲ TouĐh™ ‘eal-
Time PCR Detection System (BioRad) using the following protocol: 120 min at 50 °C, 10 
min at 95 °C 15 sec at 95 °C and 60 min at 60 °C, repeated 50 times. 
Data analysis was performed using the Comparative Ct Method, also referred as 
the ΔΔCt Method. Comparing samples requires normalization to compensate for 
differences in the amount of biological material in samples. The most current strategy is 
the normalization with internal reference gene (endogenous control MT-ATP6Ϳ. ΔΔCt 
Method is applied when the primers of target and endogenous genes has a 100 % 
efficiency. The relative expression of the two genes, ΔCT ǀalue, is calculated by following 
equation: 
Equation 7. ΔCT Equation �ܥ� = ܥ� ௧௔௥�௘௧ −  ܥ� ௘௡ௗ௢�௘௡௢ ௖௢௡௧௥௢௟  
where exponent CT (Cycle threshold) accounts for the production of double stranded 
DNA in the first PCR cycle from the single stranded cDNA template generated by the 
reverse transcription reaction. To evaluate expression level of the determined gene 
relatively to the calibrator should be performed: 
Equation 8. ΔΔCT  Equation ��ܥ� = �ܥ� ݐ݁ݏݐ ݏܽ݉݌݈݁ −  �ܥ� ݈ܿܽ�ܾݎܽݐ݋ݎ ݐ݁ݏݐ 
The amount of target, normalized to an endogenous reference and relative to a 
calibrator, is given by: 
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Equation 9. Ratio of gene expression �ܽݐ�݋ = ʹ−��஼�  
13. Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 5.0 software, using the one-
way ANOVA test, folloǁed ďǇ a DuŶŶett͛s oƌ TukeǇ͛s multiple comparison test or two-
way ANOVA test, followed Bonferroni post-test. Results were expressed as mean 
±standard deviation (S.D.), and p< 0.05 was considered to be statistically significant. 
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III. Results 
1. Physicochemical characterization of DODAX:MO:DC-Chol liposomes 
a. Hydrodynamic diameter and surface charge  
Hydrodynamic diameter and surface charge of DODAX:MO:DC-Chol liposomes were 
determined by Dynamic Light Scattering (DLS) and Electrophoretic light scattering (ɺ-
potential) (Figure 10).  
DODAX:MO:DC-Chol liposomes prepared by thin lipid film hydration method, 
followed by extrusion, presented a uniform size distribution (PdI<0.1) with 
hydrodynamic diameter between 100-120 nm and were positively charged (ɺ-
potential>44 mV). DODAB-based liposomes had slightly higher mean size and had a 
more polydisperse population than DODAC-based liposomes. No significant differences 
were observed concerning the liposomal surface charge when comparing the two 
counterions. The inclusion of DC-Chol in liposomal formulations, at lower contents (10 
% in the formulation 5:4:1), maintain or decreased the Z-average of DODAB and DODAC-
based liposomes, respectively. At higher contents (16 % in formulation 4:1:1), DC-Chol 
increases both DODAB and DODAC-based liposomes mean sizes. DODAB:MO:DC-Chol 
Figure 10. Z-average mean size (nm), (columns), Polydispersity Index (PdI), (values on 
top of the size columns), and ζ-potential (mV), (circles), of DODAB:MO:DC-Chol (B) and 
DODAC:MO:DC-Cho l(C) (2:1:0; 5:4:1 and 4:1:1) ratios liposomes. Data are presented 
as mean ± standard deviation (S.D.) obtained from two independent experiments. 
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(4:1:1) and DODAC:MO:DC-Chol (4:1:1) presented the highest values of hydrodynamic 
diameter, 115 nm and 109 nm, respectively.  
Post-pegylation maintained or decreased the mean size and the polydispersity of 
the liposomes (100-120 nm) (PdI<0.1), except for DODAB:MO:DC-Chol (2:1:0) 
formulation, where post-pegylation increased the liposomes mean size from 107.6 nm 
(non-pegylated) to 112.9 nm (pegylated). Pegylated DODAB-based exhibited higher 
mean size values compared with pegylated DODAC-based liposomes. Also, the mean 
size of pegylated liposomes seems to be dependent on DC-Chol content. In DODAB-
based liposomes, the higher the DC-Chol content, the lowest the mean size of liposomes. 
Pegylated DODAC:MO:DC-Chol (5:4:1 and 4:1:1) exhibited the lowest values of mean 
size (93 nm) while pegylated DODAB:MO:DC-Chol (2:1:0) presented the highest mean 
size (113 nm). 
All MO-based liposomes presented siŵilaƌ ɺ-potential values. Moreover, higher 
contents of cationic lipids in DODAX:MO:DC-Chol (4:1:1) (82 % mol:mol of DODAX + DC-
Chol) did Ŷot ƌesult iŶ higheƌ ɺ-potential values when compared to the other 
DODAX:MO:DC-Chol dispersions.  
Our data showed that the post-pegylation reduced, significantly, the liposomes 
surface charge (around 20 mV). No significant changes in the ɺ-potential values were 
detected between pegylated DODAB and DODAC-based liposomes.  
In pegylated DODAB-ďased liposoŵes, ;ϱ:ϰ:ϭͿ liposoŵes pƌeseŶted the highest ɺ-
potential (33.5 mV), followed by (2:1:0) (24.9 mV), and then (4:1:1) (20.2 mV), while for 
DODAC-ďased liposoŵes the ɺ-potential slightly increases with the increase of DC-Chol. 
DODAC:MO:DC-Chol ;Ϯ:ϭ:ϬͿ liposoŵes pƌeseŶted the highest ɺ-potential (22.2 mV), 
followed by (5:4:1 with 10 % of DC-Chol) (23.8 mV), and then (4:1:1 with 16 % DC-Chol) 
(25.3 mV). 
DODAB:MO:DC-Chol (5:4:1) formulation presented the highest value of surface 
charge (33 mV) and DODAB:MO:DC-Chol (4:1:1) the lowest value of surface charge (20 
mV). 
b. Stability over time of non-pegylated liposomes 
The mean size aŶd ɺ-potential of the non-pegylated DODAX:MO:DC-Chol liposomes 
were monitored over 30 days (Figure 11). 
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Figure 11. Stability over time of non-pegylated DODAB/C:MO:DC-Chol liposomes. Z-average 
mean size (nm) (1); Polydispersity Index (PdI) (2) and ζ-potential (mV) (3) of DODAB:MO:DC-Chol 
(B) and DODAC:MO:DC-Chol (C) liposomes over 30 days. Data are presented as mean ± S.D. 
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All MO-based liposomes were stable in HEPES buffer solution (pH 7.4, 25 mM) for 
this period of time in teƌŵs of ŵeaŶ size, PdI aŶd ɺ-potential. 
c. Evaluation of lipid mixing/fusion ability of non-pegylated liposomes 
Endosomal escape is determinant for a successful gene silencing and depends on 
the nanocarriers ability to destabilize/fuse with the endosome membranes. In order to 
mimick early and late endosomes, the fusogenic ability of DODAX:MO:DC-Chol 
liposomes was evaluated at neutral and acidic conditions,  by Foster Resonance Transfer 
(FRET) assay, using the pair NBD-PE (donor) and Rho-PE (acceptor) fluorescence probes 
(Figure 12). 
 
 Figure 12. Ability of non-pegylated DODAX:MO:DC-Chol liposomes to destabilize model 
endosomal membranes, as assessed by FRET. (A) FRET efficiency (ϕFRET) after incubation of 
DODAB:MO:DC-Chol liposomes with model early endosomes (pH 7.2). (B) ϕFRET after incubation 
of DODAB:MO:DC-Chol liposomes with model late endosomes (pH 5.5). (C) ϕFRET after 
incubation of DODAC:MO:DC-Chol liposomes with model early endosomes (pH 7.2). (D) ϕFRET 
after incubation of DODAC:MO:DC-Chol liposomes with model late endosomes (pH 5.5). Control-
model of early or late endosomes in the absence of DODAX:MO:DC-Chol liposomes, 
(DODAB:MO:DC-Chol (B) and DODAC:MO:DC-Chol (C)) corresponding to maximum ΦFRET. Data 
are presented as mean ± S.D. obtained from two independent experiments. 
All MO based liposomes exhibited a reduction in FRET signal at both pH 7.2 and pH 
5.5, suggesting a lipid mixing/fusogenic ability of the nanocarriers to interact with 
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early/late endosomes. DODAB-based nanocarriers exhibited a similar reduction in FRET 
signal for both pH while DODAC-based exhibited a more pronounced reduction in acidic 
pH. The inclusion of DC-Chol in nanoformulation (10 % in 5:4:1 and 16 % in 4:1:1) 
increased lipid mixing/ fusogenic ability between nanocarriers and early/late endosomal 
model when compared to DODAX:MO:DC-Chol (2:1:0) liposomes. Moreover, an increase 
in the amount of DC-Chol from 10 % in (5:4:1) formulation to 16 % in (4:1:1) formulation 
resulted in a higher fusogenic capacity of the liposomes at both pH conditions. 
DODAB:MO.DC-Chol-based (4:1:1) nanoformulation promoted a decrease in FRET in of 
34 % and in 38 % while DODAC-based liposomes (4:1:1) promoted a reduction in 50 % 
and in 55 % at pH 7.2 and pH 5.5. A slightly decrease on FRET over time is detected for 
both DODAB and DODAC-based nanocarrier, which was more pronounced in acidic 
conditions in case of the DODAC-based liposomes comparing with DODAB-based 
liposomes. The fact that the formulation DODAX:MO:DC-Chol (5:4:1) possess higher MO 
content (40 %) did not provide higher fusogenic capacity when compared with 
formulations with lower MO content (33 % in 2:1:0 and 16 % in 4:1:1 formulations). 
2. Biophysical characterization of DODAX:MO:DC-Chol siRNA-lipoplexes 
a. Small interference RNA encapsulation efficiency 
RiboGreen assay uses a RNA intercalating fluorescence probe to quantify RNA in 
solution. RiboGreen assay was performed to calculate the siRNA encapsulation 
efficiency of MO-based liposomes. In Figure 13, it is possible to visualize the siRNA 
encapsulation dynamics of non-pegylated DODAX:MO:DC-Chol formulations. 
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Figure 13. siRNA encapsulation  efficiency by non-pegylated DODAB/C:MO:DC-Chol 
(DODA liposomes at different C.R.. DODAB:MO:DC-Chol (B) and DODAC:MO:DC-Chol (C). 
0 % indicates the higher degree of RiboGreen intercalated in a free siRNA solution with 
the same siRNA concentration as used in the siRNA-lipoplexes. Data are presented as 
mean ± S.D. obtained from two independent experiments. 
All DODAB-based formulations exhibited the same dynamics of siRNA 
encapsulation, independently on the lipids content. In DODAC-based liposomes, the 
inclusion of DC-Chol significantly improved siRNA encapsulation efficiency at lower CR 
(+/-) (<5), with DODAC:MO:DC-Chol (2:1:0) only reaching its maximum siRNA 
encapsulation at CR (+/-)5. Nevertheless, it is the lowest content of the DC-Chol (10 %) 
balanced with a high MO content (40 %) in DODAC:MO:DC-Chol (5:4:1) formulation, that 
promoted the better siRNA encapsulation efficiency when compared to all the other 
formulations. However, with the increase of charge ratio (+/-) (>5), all formulations 
presented approximately the same siRNA encapsulation efficiency (>97 %). 
b. Hydrodynamic diameter and surface charge of DODAX:MO:DC-Chol siRNA-lipoplexes  
In order to determine the charge ratio with the best features in terms of size, PdI 
aŶd ɺ-potential, Dynamic and Electrophoretic Light Scattering measurements where 
performed in lipoplexes prepared at the charge ratios with the highest siRNA 
encapsulation efficiencies, namely CR (+/-) 5,7 and 10 (supplementary material). Figure 
14 revealed the physicochemical characterization of lipoplexes and post-pegylated 
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lipoplexes at charge ratio (+/-) 7, since at this CR we considered that maximum siRNA 
encapsulation was already achieved, while the excess of lipid added to siRNA was still 
acceptable. Moreover, we intend to avoid empty liposomes but not lacking totally 
particle formation. 
 
Figure 14. Z-average mean size (nm) (columns), Polydispersity Index (PdI) (value above 
the columns), and ɺ-potential (mV) of non-pegylated (black circumferences) and post-
pegylated DODAB/C:MO:DC-Chol siRNA-lipoplexes (white circumferences). 
DODAB:MO:DC-Chol (B) and DODAC:MO:DC-Chol (C).  Data are presented as mean ± 
S.D. obtained from two independent experiments. 
The mean size and surface charge of non-pegylated lipoplexes were slightly higher 
than the corresponding liposomes (111-140 nm and > +38 mV) (Figure 13), and despite 
of the increased polydispersity of the population, the values of PdI were lower than 0.2. 
The post-pegylation did not increased the hydrodynamic diameter of lipoplexes and 
maintain the polydispersity of the dispersions, except for DODAC:MO:DC-Chol (5:4:1), 
where both mean size and polydispersity were increased from to 112 nm with PdI of 
0.12 to 154 nm with PdI of 0.3. 
Pegylation efficiently reduces the lipoplexes surface charge to around +20 mV, and 
no significant differences between DODAB and DODAC-based lipoplexes were observed. 
However, pegylation of nanoformulations including lower contents of DC-Chol (10 % in 
5:4:1 formulation), seems to be more efficient in decreasing the surface charge (from 
48 to 17 mV in DODAB-based and from 45 to 18 mV in DODAC-based nanoformulations) 
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than those with higher contents of DC-Chol (16 % in 4:1:1 formulation) (from 47 to 21 
mV in DODAB-based and from 38 to 22 mV in DODAC-based nanoformulations). 
c. Effect of colon fluids mimicking solution on size stability of the pegylated  DODAB:MO:DC-
Chol (5:4:1 and 4:1:1) siRNA-lipoplexes  
Although local siRNA delivery to the intestine is an attractive approach, the 
components of intestinal fluids, namely intestinal and nuclease enzymes, the mucus 
lining, the gut flora, as well as the pH range, are significant challenges for successful 
siRNA delivery. Therefore, nanocarriers stability is necessary for siRNA protection and 
consequently efficient siRNA delivery to the target sites. Preliminary studies of 
lipoplexes stability in a solution, previously described113, mimicking the colon, content 
was performed to evaluate the possibility of local nanoparticle administration. 
The effect of the colon fluids mimicking solution in the stability of pegylated 
DODAB:MO:DC-Chol lipoplexes was evaluated by Dynamic Light Scattering and is 
presented in Figure 15. 
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Figure 15. Effects of a colon fluid mimicking solution in the stability of pegylated DODAB:MO:DC-
Chol siRNA-lipoplexes. Colon fluid (A); DODAB:MO:CH-Chol lipoplexes (5:4:1) (B) and 
DODAB:MO:CH-Chol (4:1:1) lipoplexes (B1) in HEPES buffer measurements after 24 h at 37 °C; 
DODAB:MO:CH-Chol lipoplexes (5:4:1) (C) and DODAB:MO:CH-Chol (4:1:1) lipoplexes (C1) 
incubated in colon fluid mimicking solution at time point zero;  DODAB:MO:CH-Chol lipoplexes 
(5:4:1) (D) and DODAB:MO:CH-Chol (4:1:1) lipoplexes (D1) incubated in colon fluid mimicking 
solution during 30 min at 37 °C;  DODAB:MO:CH-Chol lipoplexes (5:4:1) (E) and DODAB:MO:CH-
Chol (4:1:1) lipoplexes (E1) incubated in colon fluid mimicking solution during 24 h at 37 °C. Data 
are presented as intensity (%) resulted from 5 measurements. 
The colon fluid mimicking solution was diluted in HEPES buffer (1:1 v:v) to account 
for the dilution that occurs when it is incubated with the liposomes. The colon fluid 
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mimicking solution was found to present two major populations, where the mean size 
of the particles in population 1 was 365 ± 17 nm (90 % of intensity), and 5088 ± 264 nm 
(10 % of intensity) in population 2, with a high PdI value (0.5) (Figure 15.A).  
The pegylated DODAB:MO:DC-Chol (5:4:1) and DODAB:MO:DC-Chol (4:1:1) 
lipoplexes exhibited mean sizes of 107 ± 3 nm and 130 ± 5 nm, respectively, with 
polydispersity index lower than 0.1. In order to evaluate the effect of the physiological 
temperature in the size stability of both lipoplexes, they were incubated in HEPES buffer 
(25 mM, pH 7.4) (1:1 v:v) during 24 h at 37 °C. Both pegylated DODAB:MO:DC-Chol 
(5:4:1) (Figure B) and DODAB:MO:DC-Chol (4:1:1) (Figure 15.B1) lipoplexes presented a 
similar unique population with mean sizes of 118 ± 4 nm and 132 ± 4 nm, respectively, 
with lower polydispersity (<0.09), similar to corresponding lipoplexes. The temperature 
of the body did not promote significant aggregation of the nanoparticles. 
Immediately after incubation of DODAB:MO:DC-Chol (5:4:1) siRNA-lipoplexes  with 
the colon fluid mimicking solution (1:1 v:v) (time point zero, Figure 15.D), it was possible 
to observe three populations: a population with mean size around 260 nm (with 60 % of 
intensity), a population with mean size around 2000 nm (with 30 % of intensity) and 
finally, a population with mean size higher than 3000 (with 10 % of intensity). After 30 
min at 37 °C (Figure 15.D), the three populations were maintained. However, after 24 h 
(Figure 13.E) of exposure, two major populations were detected, one with a mean size 
around 400 nm (with 64 % intensity) and another population with mean size around 
2044 nm (with 33 % intensity). 
After the incubation of DODAB:MO:DC-Chol (4:1:1) lipoplexes with the mimicking 
colon fluid solution (1:1 v:v) (time point zero), two major populations were observed in 
Figure 13.C: a population 1 with mean size around 300 nm (with 78 % of intensity) and 
a population 2 with higher mean sizes, around 3000 nm (with 21 % of intensity). After 
30 min at 37 °C (Figure 15.D), the diameter of the population 1 increased to 960 nm and 
the intensity diminishing to 60 %, but the intensity of the population 2 increased (40 %), 
maintaining a mean size around 3000 nm. After 24 h incubation (Figure 13.E), it was 
possible observe that the major populations maintained their mean sizes, but also, 
another population appeared with 70 nm of diameter (10 % of intensity). 
For short periods of time, both pegylated formulations maintain their mean sizes in 
colon fluid mimicking solution, however, with the increase of the period of exposure, 
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the populations begin to aggregate, which is visible by the increase of the second 
population with highest mean sizes. 
3. Biological validation of siRNA-delivery systems 
a) Hemocompatibility of non-pegylated liposomes 
The determination of the hemocompatibility of a drug delivery system is an 
essential pre-requisite for its systemic blood administration. The small size and unique 
physicochemical properties of nanocarriers may cause unknown interactions with 
blood, more precisely with erythrocytes. Therefore, in vitro evaluation of their 
hemocompatibility is necessary for early preclinical development. The most common 
test to evaluate erythrocytes interactions with nanovectors is the evaluation of 
hemoglobin released after incubation with blood. Hemolysis assays are generally 
considered valuable in testing the hemocompatibility of a drug formulation. A standard 
hemolysis assay was performed to evaluate the hemocompatibility of MO-based 
nanocarriers (Figure 16). It is worth mentioning that hemolysis percentage between 5 
and 25 % are described as ͚Ŷo ĐoŶĐeƌŶ͛114.  
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Figure 16. Lysis of erythrocytes after 30 min of exposure to non-pegylated DODAB/C:MO:DC-Chol 
at 5, 25 and 50 µg/mL. DODAB:MO:DC-Chol (B) and DODAC:MO:DC-Chol (C).  Data are presented 
as mean ± S.D. obtained from two independent experiments with freshly pig blood. The ANOVA 
statistical test was perfoƌŵed, followed by a Tukey’s multiple comparison test.*p< 0.05,**p< 
0.01, and***p< 0.001.  
Figure 16 shows that all MO-based nanocarriers induced low percentages of 
hemolysis (0-20 %). Since it is known that incubation of erythrocytes with Triton X-100 
and distillated water results in around 100 % cell lysis and consequent hemoglobin 
release, these were used as positive controls in the hemolysis assay114. Figure 15 shows 
that HEPES buffer (pH 7.4, 25 mM) induced about 3 % of hemolysis. All MO-based 
nanoformulations induced significant hemolysis when compared to a negative control 
made with PBS buffer (p<0,001), with the exception of DODAB:MO:DC-Chol (5:4:1 and 
4:1:1) (p<0.05) and DODAC:MO:DC-Chol (2:1:0 and 4:1:1) formulations (p<0.01) at the 
lowest tested concentration. 
The inclusion of DC-Chol in DODAB-based nanocarriers significantly reduced the 
erythrocytes damage at the highest concentrations tested. Moreover, DODAB:MO:DC-
Chol ( 16 % of DC-Chol in 4:1:1 formulation ) diminished hemolysis compared with all 
other MO-based liposomes. The inclusion of DC-Chol in DODAC-based liposomes only 
reduced the damage to erythrocytes at the highest content and concentration of 
liposomes (16 % of DC-Chol and 50 µg/mL) (p<0.01). In general, DODAC-based liposomes 
induced a higher damage to the erythrocytes than DODAB-based liposomes, although 
not being statistically significant. 
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b. Evaluation of DODAX:MO:DC-Chol liposomes cytotoxicity 
Cytotoxicity induced by pegylated and non-pegylated DODAX:MO:DC-Chol 
liposomes was evaluated in the colon carcinoma cell line RKO by SRB and MTT assays. 
i. Effects of DODAX:MO:DC-Chol in cell proliferation 
The changes in cell proliferation induced by pegylated and non-pegylated 
DODAX:MO:DC-Chol liposomes, at different concentrations, was evaluated by the SRB 
assay (Figure 17). The buffer where the nanocarriers are prepared (HEPES buffer) does 
not interfere with DODAX:MO:DC-Chol toxicity, neither for the higher concentrations 
used.  
 
Figure 17. Evaluation of cytotoxicity induced on cell proliferation by non pegylated and pegylated 
DODAB/C:MO:DC-Chol  on RKO cells, as determined by SRB assay after 48 h of lipid exposure at 
5, 25 and 50 µg/mL. DODAB:MO:DC-Chol  (B) and  DODAC:MO:DC-Chol (C). Data are presented 
as mean ± S.D. obtained from three independent experiments. The ANOVA statistical test was 
performed, followed by a Dunnett’s multiple comparison test.*p< 0.05,**p< 0.01, and***p< 
0.001. 
The cytotoxicity of MO-based liposomes depends on the counterion. DODAB-based 
liposomal formulations do not significantly reduced cell proliferation, even at higher 
concentrations, and the presence of DC-Chol inclusion did not significantly interfere with 
the DODAB-liposomes cytotoxicity.  
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Contrarily, a significant reduction on cell proliferation was observed for DODAC-
based nanoformulations, depending on the lipids proportion and concentration. At 
higher concentrations (25 and 50 µg/mL), all DODAC formulations induced a significant 
reduction in cell proliferation (p< 0.001). Additionally, the increase of DC-Chol seems to 
increase the nanocarriers toxicity when it comes to cell proliferation. An exception was 
observed for the lowest concentration tested (5 µg/mL), where the presence of 10 % of 
DC-Chol (in formulation (5:4:1)) induced less cytotoxicity (p<0.001). 
In general, the cell proliferation was not affected by the pegylation of the MO-based 
nanocarriers. Particularly, pegylated DODAB-based did not reduced cell proliferation, 
except for the highest concentration of DODAB:MO:DC-Chol (5:4:1) formulation when 
compared to control and non-pegylated formulations (p<0.05). In DODAC-based 
liposomes, only the pegylated DODAC:MO:DC-Chol (2:1:0 formulation at 5 and 25 
µg/mL) and DODAC:MO:DC-Chol (4:1:1 formulation at 5 µg/mL) did not reduced cell 
proliferation when compared to the control cells. Also, when compared with the 
correspondent non-pegylated formulations (which reduced significantly cell 
proliferation), pegylation actually promoted some cellular proliferation. 
ii. Effects of DODAX:MO:DC-Chol in cellular metabolic activity 
Metabolic cytotoxicity of non-pegylated and pegylated DODAX:MO:DC-Chol delivery 
systems at different concentrations was evaluated by the MTT assay (Figure 18). The 
buffer where the nanocarriers are prepared (HEPES buffer) does not contribute to the 
DODAX:MO:DC-Chol liposomes toxicity, neither at higher concentrations.  
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Figure 18. Metabolic cytotoxicity induced by non pegylated and pegylated DODAB/C:MO:DC-
Chol  on RKO cells, evaluated by the MTT assay after 48 h of lipid exposure at 5, 25 and 50 µg/mL. 
DODAB:MO:DC-Chol  (B) and  DODAC:MO:DC-Chol (C). Data are presented as mean ± S.D. 
obtained from tree independent experiments. The ANOVA statistical test was performed, 
followed by a DuŶŶett’s multiple comparison test.*p< 0.05,**p< 0.01, and***p< 0.001. 
Figure 18 showed that MO-based liposomes cytotoxicity was counterion-
dependent. In absence of PEG, DODAB-based nanocarriers did not significantly reduce 
the metabolic activity of the colorectal cells (metabolic activity>75 %). The inclusion of 
DC-Chol had no effect on the vector toxicity compared with non-treated cells. In the case 
of DODAC-based nanocarriers, cytotoxicity is clearly concentration and DC-Chol 
dependent (p<0.001). In fact, even with 5 µg/mL, the formulation with the higher 
content of DC-Chol (16 %) already induced metabolic cytotoxicity (p<0.001). Moreover, 
increasing the concentration of the nanocarrier along with DC-Chol content, resulted in 
a substantial increase on the nanocarriers toxicity. DODAC:MO:DC-Chol (2:1:0) reduced 
the metabolic activity of the cells (p<0.01) at both 25 and 50 µg/mL concentrations when 
compared to the control cells. The inclusion of the DC-Chol at 10 or 16 % (in proportions 
5:4:1 and 4:1:1, respectively) increased the significance of metabolic activity reduction 
(p<0.001). 
The pegylation of DODAB:MO:DC-Chol liposomes did not induce significant levels of 
metabolic cytotoxicity when compared to the control cells, except in case of the 
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pegylated DODAB:MO:DC-Chol (4:1:1) liposomes at the highest concentration tested 
(p<0.05) compared to the non-pegylated formulation that exhibited cytotoxicity no 
comparing with control cells. In the case of DODAC-based formulation, non-pegylated 
2:1:0 formulation, at 25 µg/mL, induced significant toxicity (p<0.05) while pegylated one 
did not interfere in metabolic toxicity when both were compared to control cell, also in 
non-pegylated 4:1:1 formulation, at 5 µg/mL, reduced metabolic activity significantly 
(p<0.001) while pegylated one did not interfere in metabolic activity when both were 
compared to control cell. 
c. Cellular uptake of DODAX:MO:DC-Chol liposomes 
In figure 19 is represented the percentage of fluorescent labeled liposomes 
internalized by RKO cells after 6 h incubation, at 37 °C.  
 
Figure 19. Evaluation of cellular uptake of non pegylated and pegylated 
DODAB/C:MO:DC-Chol liposomes in RKO cells, as determined by fluorescence 
measurements after 6 h of lipid exposure, at 25 and 50 µg/mL. DODAB:MO:DC-Chol  (B) 
and  DODAC:MO:DC-Chol (C). Data are presented as mean ± S.D. obtained from 6 
experiments. The two-way ANOVA statistical test was performed, followed by a 
Bonferroni post-test.*p< 0.05,**p< 0.01, and***p< 0.001. 
The cellular uptake of MO-based nanocarriers was low. Actually, less of the 20 % of 
the lipid added for the both concentration tested were internalized by cells. Only for 
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DODAC-based liposomes, the cellular uptake was concentration dependent (p<0.001), 
yet the duplication of the lipid concentration maintained or decreased the cellular 
uptake. Moreover, DODAC-based liposomes seems to be better internalized than 
DODAB-base liposomes by cells (p<0.05 and p<0.001 at 25 and 50 µg/mL, respectively). 
The inclusion of DC-Chol in MO-based liposomes dispersions had a different 
behavior depending on the counterion. For non-pegylated DODAB-based nanocarriers a 
significant increase in cellular association was observed only for DODAB:MO:DC-Chol (16 
% of DC-Chol in 4:1:1 nanoformulation), for both concentrations 25 and 50 µg/mL 
(p<0.001 and p<0.01, respectively), when compared to DODAB-based liposomes 
without DC-Chol. For DODAC-based liposomes, the cellular uptake only significantly 
increased in DODAC:MO:DC-Chol (10 % of DC-Chol in 5:4:1 nanoformulation) prepared 
at 25 µg/mL, when compared to DODAC:MO:DC-Chol (2:1:0). Moreover, 
DODAC:MO:DC-Chol 5:4:1 formulation compared with DODAB:MO:DC-Chol 5:4:1 
formulation exhibited a higher cellular uptake (p>0.001) at 25 µg/mL, and also 
DODAC:MO:DC-Chol 4:1:1 nanocarrier were better internalized (p<0.01) when 
compared to DODAC:MO:DC-Chol 4:1:1 nanocarrier, at both concentrations tested.  
Interestingly, cellular uptake was increased when DODAX:MO:DC-Chol liposomes 
were post-pegylated. In DODAB-based formulations, at both concentrations, pegylation 
significantly increased the nanocarriers cellular uptake (p<0.001). Nevertheless, in 
DODAC-based liposomes, some differences were observed: pegylation of liposomes 
significantly increased the cellular uptake of the 2:1:0 formulation (p<0.001), at 25 
µg/mL, and of the 5:4:1 nanoformulation (p<0.001), at both concentrations. 
d. BRAF silencing by pegylated DODAB:MO:DC-Chol siRNA-lipoplexes 
DODAB:MO:DC-Chol (5:4:1; 4:1:1) nanocarriers have been demonstrated to be the 
more promissory vehicles for siRNA delivery revealing a suitable size for administration, 
a diminished cytotoxicity and aggregation and also a moderate cellular uptake. RKO cells 
were transfected with DODAB:MO:DC-Chol (5:4:1; 4:1:1) lipoplexes and the BRAF gene 
silencing efficiency was evaluated by qPCR (Figure 19). 
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Figure 20. BRAF gene expression in RKO cells after 48 h of siRNA transfection at 100 nM. 
Lipofectamine 200 were used as lipofection control.The nanovectors used to transfect BRAF gene 
were non-pegylated and pegylated DODAB:MO:DC-Chol (5:4:1 and 4:1:1) (experience 1 
corresponding to white columns);  non-pegylated and pegylated DODAB:MO:DC-Chol (5:4:1 and 
4:1:1) and pegylated DODAB:MO:DC-Chol (5:4:1 and 4:1:1) including 1 % PEG-FOL (experience 2 
corresponding to black columns). 
The transfection efficiency of MO-based nanocarriers and Lipofectamine 2000, used 
as a lipofection control, were compared in relation to the untreated cells, which 
expressed the highest level of the BRAF gene (expression value of 1). In Figure 20, it was 
possible to observe that in both experiences lipofectamine 2000 was not efficient in 
silencing the BRAF gene (expression value around 10). An unexpected increase in the 
expression of the BRAF gene was observed, not only for lipofectamine but also for all 
the conditions tested in the first experience (data 1) (expression value>1). In opposition, 
it was observed a reduction of the BRAF level expression by DODAB:MO:DC-Chol (4:1:1) 
lipoplexes (expression value<1), either non-pegylated (expression value of 0.7), 
pegylated with PEG-cer (expression value of 0.99) and pegylated with PEG-cer plus PEG-
FOL (expression value of 0.85) in the second experience (data 2). Moreover 
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DODAB:MO:DC-Chol (5:4:1) pegylated with or without PEG-FOL led to a reduction of 
BRAF expression of 0.63 and 0.88, respectively. 
Although the results obtained in the controls were not according to what was 
expected, this preliminary result suggest that DODAB:MO:DC-Chol might be efficient in 
silencing BRAF expression in CRC cells. 
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IV. Discussion 
The need for new therapeutic approaches for specific target therapy in colorectal 
cancer associated with the promissory results exhibited by MO-based nanocarriers led 
us to develop new lipoplexes based in DODAX:MO:DC-Chol for BRAF-siRNA delivery into 
CRC derived cells. Indeed, MO-based liposomes have been described as efficient 
nanocarriers for DNA delivery87. It has been reported that the presence of DC-Chol 
enhanced the efficiency of pDNA delivery by the MO-based nanocarriers in Embryonic 
Kidney 293T cells without inducing significant toxicity102. In alternative approach, MO-
based liposomes have been established as efficiently nanocarriers for siRNA delivery in 
H1299 eGFP cells99. Varying the proportion of DODAX to MO and changing the 
counterion from Cl- to Br-, altered the nanocarriers properties in such a way that not 
only resulted in different levels of organization, but also in internalization and different 
transfection efficiencies which, in turn, resulted in different gene silencing capability. 
Despite of dioctadecyldimethylammonium bromide (DODAB) and 
dioctadecyldimethylammonium chloride (DODAC) molecules only differ in the 
counterion (Br- and Cl-), its effect on bilayer hydration significantly influences several 
properties, like the mean size and the gel to-liquid crystalline transition temperature96-
98. 
The physicochemical properties of nanocarriers largely govern the success of every 
gene therapy strategy. The preparation method strongly influences physicochemical 
characteristics of DODAX:MO:DC-Chol, such as size and surface charge, which will 
influence the nanocarriers pharmacokinetics and determine their success in gene 
delivery. Extruded MO-based liposomes demonstrated to have better physicochemical 
features compared with liposomes prepared by ethanol injection method102. In the 
present work, MO-based nanocarriers were produced by lipid film hydration followed 
by extrusion. The lipid film hydration is known to produce a heterogeneous population 
of multilamellar vesicles, so extrusion method was required to decrease the size and 
homogenize the liposome dispersion to obtain suitable SUVs and LUVs nanocarriers for 
biological applications. The loss of lipid during extrusion was the major drawback of this 
method, despite could it be quantified, it was not possible to take into account due to 
equipment limitations (limited access to HPLC and GS-MS and the long period of 
 56 
 
optimization required for the techniques). MO-based nanocarriers were prepared in 
HEPES buffer and their physicochemical properties (size and surface charge) 
characterized by DLS assays. The size of the non-pegylated and pegylated 
DODAX:MO:DC-Chol liposomes was found to be around 100-120 nm, meeting the size 
requirements for the prevention of clogging of capillaries and nanocarrier extravasation 
throughout the fenestrae of capillaries115. Also, DODAB-based liposomes present a 
slightly higher mean size than DODAC-based liposomes, which is in accordance with the 
literature99. The counterion Br- is less hydrated and possesses a small headgroup area 
than counterion Cl-, originating weak electrostatics repulsions between DODAB 
headgroups leading to a decrease in the aggregate mean curvature, which is reflected 
by an increase in the liposomes size116,117. In DODAB bilayers the more tightly packed 
head groups hinder a homogeneous MO incorporation into the bilayers. DODAC:MO 
appears to form lamellar phases with less tight polar head groups, with MO better 
distributed, compared to DODAB:MO. Therefore, MO-rich and DODAB-rich domains are 
formed in DODAB:MO liposomes, as already published99. DSC measurements performed 
with this formulations reveal that DODAC:MO (2:1) presents a Tm =48 °C ;ΔH=Ϯϵ.Ϯ 
kJ/mol) and DODAB:MO (2:1) presented  Tm=47.1 °C ;ΔH=Ϯϱ.ϰ kJ/ŵolͿ being both 
characterized by the presence of lamellar phases99. Nevertheless, DODAC:MO (2:1) 
presents a higher enthalpy than DODAB:MO, which means the presence of more rigid 
bilayers. But not only the counterion was found to have an important effect on the 
structure of the liposomes, but also the MO content. As previously reported94, in 
DODAX-enriched formulations (DODAX:MO (2:1)) prevails lamellar phase, while, in MO-
enriched formulations (DODAX:MO (1:2)) occurs a coexistence of lamellar and 
nonlamellar phases. Nevertheless, the mean size of the liposomes remains 
approximately the same. We expected that the inclusion of a third lipid on DODAX:MO 
liposomes would change the liposomes properties and improve them as siRNA 
nanocarriers. The physicochemical characterization revealed that DC-Chol inclusion did 
not change the diameter of the nanoformulations. Although, a slight increase of the 
liposomes mean size for the higher DC-Chol content tested (16 % in 4:1:1 formulation) 
were observed (Figure 10), were not significant when compared with all MO-based 
liposomes, as previously demonstrated102. Differential Scanning Calorimetry (DSC) 
measurements performed with DODAX:MO:DC-Chol formulations (unpublished results), 
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reveal that DODAX:MO:DC-Chol formulations have different thermodynamics 
parameters depending on the counterion and DC-Chol and MO molar fraction. 
DODAB:MO:DC-Chol (4:1:1) presents a Tm = 43.6 °C  and ΔH = ϰ.9 kJ/mol and  
DODAC:MO:DC-Chol (4:1:1) a Tm = ϰϱ.ϲ °C aŶd ΔH=ϭ.0x10-5 kJ/mol. For DODAB:MO:DC-
Chol (5:4:1) no Tm was detected in comparison with DODAC:MO:DC-Chol (5:4:1) (Tm = 47 
°C aŶd ΔH = ϳ.ϰ kJ/ŵolͿ. The pƌeseŶĐe of eƋual aŵouŶt of DC-Chol and MO in the 
formulation had the ability to increase the fluidity of the bilayers for both formulations 
but a higher extension for DODAC based formulation. These results reinforces that in 
DODAB:MO based formulations, DODAB head groups are more  tightly packed, hinder 
MO incorporation into the bilayers, resulting in the formation of MO-rich and DODAB-
rich domains, the inclusion of the same amount of DC-Chol (16 %) and MO (16 %) 
promoting an increase in the fluidity of the lipid bilayer. These results also suggest that 
DODAC allows a better and more homogeneous incorporation of MO and the presence 
of DC-Chol supported by further decreasing the enthalpy of the system.  When an excess 
of MO are present compared with DC-Chol (40 % MO, 10 % DC-Chol) (5:4:1) we would 
expect the presence of both rigid lamellar and inverted phases. Nevertheless, this result 
was not observed for the DODAB and DODAC based formulations. DODAC:MO:DC-Chol 
(5:4:1) presents a Tm=47 °C aŶd ΔH=ϳ.ϰ kJ/ŵol ďut Ŷo Tm was detected in 
DODAB:MO:DC-Chol (5:4:1). These results reinforces again a better distribution of MO 
in DODAC bilayer and that the inclusion of DC-Chol does not fluidize the membrane, 
instead it balances the fluidizing effect of MO. This conclusion is supported by the 
presence of more rigid bilayers in DODAC based system when compared to DODAB-
based system. Cholesterol and derivatives of cholesterol are well-known helper lipids 
that can either have a stabilizing or a fluidizing effect on lipid bilayers depending on lipid 
content and on the lipid bilayer fluidity or rigidity48. 
The ɺ-potential assays also revealed that all MO-based liposomes exhibited highly 
positiǀe ɺ-potentials: > +45 mV, and the inclusion of the positively charged DC-Chol 
content (10 % in 5:4:1 and 16 % 4:1:1 nanoformulation) did not change the surface 
charge of liposomes. When MO is in excess, MO is preferentially located inside bilayer 
while DODAB/C is located in outside bilayer. DC-Chol will be located always in outside 
bilayer independently of MO content, once did not self-assembly. Moreover, the 
positive charge is different for all MO based systems: 67 % in 2:1 formulation; 83 % in 
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4:1:1 formulation and 60 % in 5:4:1 formulation. Moreover, higher content of positive 
charge (83 %) did not resulted in higher liposomes surface charge. The positive charges 
also justify the good siRNA complexation observed for all formulations. 
Nanocarriers ability to destabilize and fuse with the cell membrane can be 
determinant for endosomal escape and efficient gene silencing. Endosomal escape 
ability was evaluated by performing lipid mixing/fusion assay between liposomes and 
model membranes. All MO-based nanocarriers exhibited some fusogenic capacity, 
which was expectable due to their high positive charge that favored electrostatic 
interactions with negatively charged model endosomes, as confirmed in Figure 12. 
DODAC:MO:DC-Chol formulations were shown to be more fusogenic compared to 
DODAB:MO:DC-Chol, likely a result of the more homogeneous integration of MO in 
DODAC bilayers than in DODAB due to their fusogenic potential, in accordance with 
previous work99. The inclusion of DC-Chol in the formulations promoted an increase on 
lipid mixing/fusogenic ability of liposomes to interact with early and late endosomal 
models, since Chol and derivatives promote the formation of inverted non-lamellar 
phase contributing for destabilization of the membrane. Nevertheless, the DODAC-
based liposomes seem to exhibit slightly higher fusogenicity. The absence or almost null 
enthalpy presented by these formulations suggests higher bilayer fluidization, which 
could promote good cell adhesion.  
The increased lipid mixing/fusogenic events induced by DODAC:MO:DC-Chol 
liposomes when compared to DODAB:MO:DC-Chol liposomes are more pronounced in 
acidic conditions. In neutral conditions, Cl- counterion is more hydrated than the 
counterion Br-, resulting in a difference in the liposomes hydration surface, which 
contributes for a higher curvature of the system. Yet, this is not sufficient to promote a 
higher lipid mixing ability. In acidic conditions, since there are more H+ in solution 
promoting the annulment of the charges, and also rescuing more the Cl- ions than Br+ 
ions, an increased lipid mixing ability exists and more fusogenic events occur for DODAC-
based liposomes. Contrary to what was expected, a higher content on MO did not 
provide higher fusogenic capacity, supporting that fusogenic ability depends not only of 
the fluidity of membrane, but also on the lipid distribution in membrane.  
A very important characteristic of any system for delivery purposes is its stability. 
We evaluated the stability of produced MO-based liposomes over 4 weeks. MO-based 
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liposomes exhibited a good stability in HEPES buffer solution as previously 
demonstrated in previous results where was demonstrated the time stability of MO-
based formulations prepared in Milli Q water102. Highly charged cationic liposomes ;ɺ-
potential>30 mV) exhibited colloidal stability resulting from the overcome of Van der 
Wall interactions by electrostatic repulsions that prevents particle aggregation making 
possible the prolonged storage. Although, highly charged nanocarriers strongly 
aggregate when exposed to physiological conditions difficulting particle administration, 
this can be avoided by coating them with the hydrophilic (neutral) polymer 
polyethyleneglycol (PEG)118. Previous studies by our group (unpublished results) 
demonstrated that the incorporation of 10 % mol of PEG-Cer chain 8 in DODAX:MO 
efficiently decreased siRNA-lipoplexes surface charge, improved stability in physiologic 
conditions without a highly reduced cellular uptake comparing with others mol 
percentages and higher chain of PEG-Cer, which is in accordance with previous 
studies48.The ELS and DLS measurements confirmed the decrease of the liposomes 
surface charge in about 50 % due to the presence of PEG and a stabilization of the size. 
Nevertheless, the liposomes surface charge remained positively charged, as intended 
for the promotion of interaction and binding to cell membranes. Our results reveal a low 
cellular uptake significantly increased by post-pegylation of DODAX:MO:DC-Chol 
liposomes (Figure 19). Actually, there are several reports demonstrating that 
nanocarriers pegylation decrease cell uptake119,120, but at the same time there are 
others that show an increase in the internalization107. Whether or not pegylated 
complexes adhere to cells depends on parameters such as the vesicle curvature and the 
ŵeŵďƌaŶe Đhaƌge deŶsitǇ ;σM; the average charge per unit area of the membrane; 
controlled by the molar ratio of cationic to neutral lipid), which can be controlled by lipid 
ĐhoiĐe aŶd lipopleǆes stƌuĐtuƌe. At suffiĐieŶtlǇ high σM, eleĐtƌostatiĐ iŶteƌaĐtioŶs ͞leak 
thƌough͟ eǀeŶ at high leǀels of PEG ĐoatiŶg, iŶduĐiŶg attaĐhŵeŶt to the Đells ŵeŵďƌane, 
even when pegylation prevents aggregation of the nanocarriers121. Moreover, our post-
pegylated lipoplexes are expected to lose the PEG-ceramides (and thus the PEG-coating) 
upon contact with cellular membranes and further endosomal escape. PEG-cer chain 8 
already revealed little or any inhibition of cellular uptake in chinese hamster ovary 
cells48. Non-pegylated DODAC-based liposomes present a higher cellular uptake than 
DODAB-based liposomes. Oliveira et al (2014) demonstrated the opposite, that DODAB-
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based liposomes were better internalized. The authors found that the reduced 
headgroup area of DODAB, which leads to the formation of less curved aggregates 
(confirmed by the higher size of the DODAB:MO liposomes compared to the DODAC:MO 
formulations)99, facilitates the adherence of the nanovectors to the cell surface and 
increased internalization122. However, size is not the only explanation for cellular 
internalization. Actually, in our experiments, the differences in the mean size between 
DODAB and DODAC did not justify the higher cell adhesion of DODAC-based liposomes, 
and other factors have to be considered. Moreover, a higher cellular uptake of 
DODAX:MO:DC-Chol liposomes was obtained by the authors when compared to the 
cellular uptake in RKO cells. Nevertheless, the inclusion of DC-Chol in DODAX:MO 
liposomes increased the cellular uptake, it was always dependent  onto the counterion. 
In DODAB:MO only at higher content of DC-Chol (16 % in 4:1:1 nanoformulation) 
increased cellular uptake, while in DODAC:MO this was observed only at lower DC-Chol 
contents (10 % in 5:4:1 nanoformulation), a fact that could be due to differences in the 
lipid organization and thermodynamics characteristics of the systems. Both 
formulations revealed a higher enthalpy reflecting the presence of greater amount of 
rigid nanoparticles when compared with DODAB:MO:DC-Chol (5:4:1) and 
DODAC:MO:DC-Chol (4:1:1) systems. The differences between our experiences and 
previous studies could be explained by the different cell lines used differences, RKO cells 
are considered hardly transfected cells when compared to H1299 eGFP cells. The 
incubation conditions were not the same, in fact in our work, RKO were incubated 6 h 
in HBSS buffer whose function is to maintain the pH, osmotic balance as well as provide 
water and essential inorganic ions, meaning that cells are not provided with glucose 
what could interfere with the normal growth of the cells. All these conditions could 
interfere with liposomes stability and with the way they interact with the cells. Also, low 
cell uptake could be explained also by sensitive issues of the method. 
An effective and non-toxic delivery system is the key challenge in the development 
of delivery vehicles because of the off-target side effects. In addition to the cellular 
association analysis, we performed cytotoxicity studies of the developed systems. 
DODAB-based delivery systems were better tolerated by cells than their DODAC-based 
counterparts, which is in accordance with the literature99. Despite of similar 
physicochemical characteristics of liposomes surface, the counterion exchange 
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influenced the vector toxicity, especially for higher lipid concentrations. MO and DC-
Chol content does not interfere with liposomal cytotoxicity, as described in previous 
work102. DC-Chol is a positively charged lipid with two amines and therefore it was 
expected to contribute to a higher toxicity profile, as positive charges are associated 
with higher cytotoxicity. However, the inclusion of different DC-Chol contents in the 
liposoŵal dispeƌsioŶs did Ŷot iŶduĐe diffeƌeŶt ɺ-potentials neither different cytotoxic 
effects on cell. Similarly, post-pegylation does not significantly interfere in the MO-
based nanocarriers toxicity, except in DODAC-based liposomes, where a reduced toxicity 
was observed. Moreover, the higher capacity of the DODAC-based nanocarriers to fuse 
with membranes may explain the higher cell toxicity compared with DODAB-based 
liposomes, as they could promote a destabilization of the cell membrane, particularly in 
DODAC:MO:DC-Chol (4:1:1), where both lamellar and inverted phases are present 
associated with a high fluidity of the system. Our results also show that MO-based 
liposomes were more cytotoxic when evaluated by SRB assay than MTT assay as the two 
assays evaluate different aspects123. SRB assay measures cell proliferation/protein 
content, while MTT assay provides information about the metabolic activity of the cells 
that is related to the viability of the cells. Nanomaterials and nanoparticles have been 
evaluated by their effects on the cell lines which they can interact at different levels, 
such as ROS production, cell viability, cell stress, cell proliferation, cell morphology 
phenotyping and cell–particle uptake assays. Although, of different interaction levels we 
should not underestimate the sensitivity and  reliability, correlation of the cytotoxicity 
the realistic physiological or environmental models containing cells, proteins and 
solutes124. 
Preclinical examination of nanoparticles biocompatibility usually requires studies of 
hemolysis, platelet aggregation, coagulation time, complement activation, leukocyte 
proliferation and uptake by macrophages125. Therefore, in the case of intravenous 
administration, evaluation of possible immediate toxic effect after exposure of 
nanoparticles to blood must be examined. To study some possible adverse effects on 
blood components, we performed an hemocompatibility assay by analyzing hemoglobin 
release after incubation of blood cells with DODAX:MO:DC-Chol liposomes. The surface 
properties of the nanoparticles play an important role and can directly damage 
erythrocytes membranes126, the non-pegylated MO-based liposomes produced present 
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similar surface proprieties, especially in terms of surface charge. All-MO-based systems 
induced a percentage of hemolysis lower than 15 % and, according with several studies 
in vitro, a percentage lower thaŶ Ϯϱ % is ƌated as ͚Ŷo ĐoŶĐeƌŶ͛125. The red blood cells 
damage was diminished by the inclusion of DC-Chol in both DODAB and DODAC-based 
nanocarriers. Derivatives of cholesterol are described in literature as promoting stability 
in vivo and in vitro, which could contribute for the diminished erythrocytes damage 
promoted by the presence of DC-Chol. Moreover, DODAB-based delivery systems 
induced lower erythrocytes damage than DODAC-based formulations, which is in 
accordance with cytotoxicity assays, and can also be explained by the lower cell uptake 
of non-pegylated nanoformulations. The hemocompatibility of post-pegylated 
liposomes was not evaluated, as hemolysis of all MO-based liposomes was considered 
harmless. The fact that we had to use of pig blood instead of human blood can be a 
limitation of our studies as it will not give results that can be immediately translated to 
humans. The removal of the plasma components prior to the incubation of the 
erythrocytes with the liposomes is another limitation, since the adsorption of plasma 
proteins onto the nanocarriers surface can have an important influence on the 
interactions between the cells and the nanoparticles. The blood coagulation as the 
anticoagulant used could also contribute to false negatives, once erythrocytes in the clot 
cannot interact with nanovectors being protected from hemolysis. The blood clots 
would be removed from the supernatant by centrifugation not contributing for the 
hemolysis measurements. To overcome these drawbacks, the hemolysis studies should 
be supported with platelet aggregation studies110. However, this assay can already give 
us an indication for a good MO-based liposomes hemocompatibility and thus for a 
possible intravenous administration. 
All MO-based nanoformulations achieved a high siRNA complexation efficiency 
(around 97 %) at low charge ratios (+/-) 5. Even though MO and DC-Chol induced a 
different degree of fluidity to the liposome bilayers, as detected by DSC assays, and 
consequently a different dynamic in siRNA encapsulation, the final siRNA complexation 
ability of the DODAX:MO:DC-Chol liposomes was not affected. The siRNA complexation 
is a dynamic process and, despite the degree of complexed siRNA being approximately 
100 % for high charge ratios, there was no indication that the siRNA molecules were 
completely incorporated inside the lipoplexes nanocarriers. The mean size, PdI, as well 
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as ɺ-potential values are parameters that can indicate whether the lipoplexes were 
completely formed or not. Hence, we performed DLS measurements for the siRNA-
lipoplexes prepared at increasing charge ratios, and the results have shown that, a CR 
higher than (+/-) 7, all MO-nanocarriers features reached a plateau (supplementary 
material), indicating that lipoplexes were fully formed. In a post-pegylation, lipoplexes 
were obtained by first preparing the lipoplexes and, subsequently, coating them with 
PEG-ceramides chains, which spontaneously adsorb to the lipoplexes surface. So in a 
post-pegylation the encapsulation efficiency is not compromised and also did not 
interfere in lipid organization of the particle104. Moreover, post-pegylation process did 
not destabilize the liposomes hence encapsulated siRNA was not able to escape from 
the liposomes (unpublished results). Since it is known that an excessive amount of highly 
charged cationic liposomes is detrimental in terms of lipid toxicity to the cells, lipoplexes 
were prepared at charge ratio (+/-) 7 for cellular studies, to ensure maximum siRNA 
loading and low lipid-induced cytotoxicity as an excess of empty liposomes could 
compete with lipoplexes in cell uptake process. For all formulations, both non-pegylated 
and pegylated DODAX:MO:DC-Chol siRNA-lipoplexes prepared at charge ratio (+/-) 7 
exhibited similar sizes (100-ϭϱϬ ŶŵͿ aŶd positiǀe ɺ-potentials: > +45 mV and > +17 mV, 
respectively. It is important to achieve a balance between siRNA protection and release 
from the lipoplexes to achieve biological functionality. siRNA-lipoplexes disassembly is 
essential to allow endosome escape and interaction with intracellular components such 
as RISC, in order to mediate RNA gene silencing. Depending on the type of 
administration, the nanocarriers will have to face different challenges. For instance, in a 
local rectal administration, the components of intestinal fluids, namely intestinal and 
nuclease enzymes, the mucus lining, the gut flora as well as the range of pH are 
significant challenges of successful siRNA delivery. In this study, a mimicking colon fluid 
(pH 6.0) was used to perform preliminary studies of lipoplexes stability for local rectal 
administration. The effects of mimicking colon fluid on siRNA-lipoplexes aggregation 
were evaluated by DLS measurements. Some reports refer that cholesterol or 
cholesterol derivatives, such as DC-Chol, promote in vivo and in vitro stability100,101, in 
our formulations, the higher stability was reached with the pegylated siRNA-
DODAB:MO:DC-Chol (5:4:1) lipoplexes containing the lower content of DC-Chol (10 %). 
Nevertheless, even if pegylated siRNA-lipoplexes seemed stable through a short period 
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of time, after 24 h of incubation, lipoplexes aggregated. Highly packed and dense 
lamellar structures with lower curvatures were found to be less destabilized when in 
physiologic mimicking conditions, and could also achieve higher transfection 
efficiencies127. As discussed above, DODAB-based lipoplexes in 4:1:1 proportion 
presented lamellar structures, while in 5:4:1 formulation no rigid lamellar structures 
were detected (absence of Tm). Despite the lipoplexes presenting lamellar phase were 
the less subjected to aggregation and/or disintegration, it was the formulation with both 
structures lamellar and inverted that presented less aggregation. Some approaches are 
described in the literature in order to maximize stability in complexes fluids such as 
colon fluid, such as coating the liposomes with polymers such poly(epsilon-
caprolactone) (PCL)41.  
Finally, the BRAF expression silencing using non-pegylated and pegylated 
DODAB:MO:DC-Chol (5:4:1 and 4:1:1) lipoplexes was evaluated and compared to a 
commercial lipofection control, Lipofectamine® 2000, previously validated by our 
group17. The lipofection control did not silence BRAF expression in both experiences 
when analysed by qPCR. Contrariwise, lipofectamine increased the levels of BRAF 
expression. In one of the experiments, despite of the lipofection control did not work, 
BRAF expression was silenced by DODAB:MO:DC-Chol. In fact, pegylated 
DODAB:MO:DC-Chol (5:4:1) exhibited higher BRAF silencing comparing with all 
formulations even when formulations include PEG-ceramide and a possible target such 
as PEG-Folate that improves internalization when Folate is overexpressed in cells. The 
overexpression of BRAF with the control of lipofection, is difficult to explain although it 
might be due to damages in siRNA or in the lipofectamine or in the qPCR primers. In 
previous experiment we used GAPDH gene as an endogenous control that has been used 
in literature to normalize BRAF expression, however, BRAF expression levels were 
always above cell control (supplementary materials). In subsequent experiences 
mitochondrial gene, MT-ATP6 gene were used to normalize expression of the gene, 
wherein the experiments, BRAF levels were below cell control. We can hypothesize that 
BRAF siRNA could be damaged or promoted unspecific interactions or the qPCR BRAF 
primers were not appropriated/specific for BRAF amplification and could be detecting 
genomic DNA. 
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V. Conclusion and future perspectives 
The work described here has important implications for the design of new 
nanocarriers for siRNA delivery. The combination of the nanocarriers components must 
be carefully optimized, once liposomal structural organization and membrane 
properties were highly dependent on the specific mixture between the neutral lipid MO 
and the cationic lipid DODAC or DODAB and DC-Cholesterol. Previous studies 
demonstrated that hanging the counterion Cl- by Br- altered the nanocarriers properties 
in such a way that defined the silencing efficiency. All MO-based liposomes exhibited 
similar physiochemical characteristics such as size and surface charge. All MO-based 
nanocarriers exhibited some fusogenic capacity, which was expectable due to their high 
positive charge that favored electrostatic interactions to anionic model endosomes. 
DODAC-based liposomes also presented higher fusogenic capacity than DODAB-based 
liposomes mainly, with the inclusion of DC-Chol (16 % in 4:1:1 nanoformulation). The 
more homogeneous distribution of MO and also DODAC hydration surface may explain 
the higher fusogenic capacity, more pronounced in acidic conditions. Also, all 
nanocarriers formulations achieved good complexation efficiency at lower charge ratios. 
Post-pegylation efficiently decrease liposomes and lipoplexes surface charge without 
alter particle features. The nanocarriers remain positively charged for further cell 
adhesion. Moreover, post-pegylation increased cellular uptake of all MO-based 
nanovectors, with DODAC-based liposomes achieving better ratios of internalization 
than DODAB-based liposomes. However, DODAC-based nanocarriers are massively toxic 
in RKO cells, mainly in higher tested concentrations which could be also explained by 
higher fusogenic capacity. Our preliminaries studies of local and intravenous 
administration were performed and showed that all MO-based nanovectors exhibited 
loǁeƌ ǀalues of heŵolǇsis ;<ϮϬ %Ϳ, ǁhiĐh is ƌated as ͚Ŷo ĐoŶĐeƌŶ͛ foƌ intravenous 
administration. Also, the size aggregation of the pegylated DODAB:MO:DC-Chol (5:4:1 
and 4:1:1) lipoplexes, for being the more promissory nanocarriers, were evaluated in a 
mimicking colon fluid solution (pH 6) for a possible local administration, yet, 
formulations seems to aggregate in this physiological conditions after a long period of 
exposure. 
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The BRAF silencing quantification by qPCR for the developed nanocarriers needs 
further optimization. Although, our preliminary results suggest that DODAB:MO:DC-
Chol (5:4:1 and 4:1:1) could be a promissory nanovectors for a specific siRNA therapy 
for CRC.  
“eǀeƌal assaǇs should ďe peƌfoƌŵed iŶ oƌdeƌ to oďtaiŶ a ͞pƌoof of ĐoŶĐept͟. 
Considering BRAF silencing optimization using the produced nanocarriers, BRAF protein 
expression should also be analyzed by Western Blot in order to confirm a technical 
problem in the siRNA oligos or in the qPCR. After optimization of the silencing we should 
analyze some phenotypic alterations already associated to BRAF inhibition such as 
apoptotic and proliferative assays. Moreover, mimicking intestinal fluids could be used 
to incubate cells in the same the conditions of intestine and further evaluate the 
transfection efficiency. Considering the nanoparticles techniques, such as confocal and 
flow cytometry, should be performed to evaluate liposomes and lipoplexes cellular 
uptake using specific markers of endocytic pathways: clathrin-mediated and caveolae-
mediated endocytosis and macropinocytosis. Moreover, intracellular trafficking and 
interactions of the nanocarriers should be analyzed using a quantitative method based 
on spatio-temporal image correlation spectroscopy (STICS) that allows for characterizing 
the mode of motion of nanocarriers and for quantifying their transport parameters as 
they move through the cytosol in a living cell. Additionally, a more physicochemical 
characterization of the nanocarriers should be performed to correlate the 
physicochemical characteristics of the nanocarriers with the efficiency in siRNA delivery, 
for a better understand of all process resulting in improved nanovectors design. Assays 
such as small angle x-ray scattering to analyze the liposomes and lipoplexes structures, 
as differential scanning calorimetry of the lipoplexes to understand how siRNA interfere 
in the fluidity of the system, as well as its implications. Also, endonucleases and 
protection assays should be performed to evaluate the capacity of the nanocarriers in 
siRNA protection in different physiological mediums using fluorescence correlations 
spectroscopy and correlate to the different lipid organization as its structures.  
Summing up DODAB:MO:DC-Chol lipoplexes developed in this work are promising 
formulations for siRNA delivery into RKO CRC cells, although, further tests will be 
necessary for the validation of these nanocarriers. These formulations might bring new 
avenues for siRNA gene silencing as a therapeutic approach in CRC.   
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VII. Suplementary Materials 
 
Table 1. Thermodynamic parameters of neat DODAX and DODAX:MO:DC-Chol liposomes 
obtained by DSC measurements (heating mode). 
 
 Ts  
(oC) 
ΔHs 
(kJ/mol) 
ΔT1/2  
(oC) 
Tm  
(oC) 
ΔHm 
(kJ/mol) 
ΔT1/2  
(oC) 
DODAC:MO:DC-Chol (2:1:0) - - - 48.3 29.2 0.8 
DODAC:MO:DC-Chol (4:1:1) - - - 45.6 1.0x10-5 1.26 
DODAC:MO:DC-Chol (5:4:1) - - - 47.0 7.4 1.44 
 
DODAB:MO:DC-Chol (2:1:0) 
 
- 
 
- 
 
- 
 
47.1 
 
25.4 
 
0.94 
DODAB:MO:DC-Chol (4:1:1) 34.6 0.12 1.3 43.6 4.9 0.93 
DODAB:MO:DC-Chol (5:4:1) - - - - - - 
 
 
 
Figure 1. BRAF gene expression in RKO cells after 48 h of siRNA transfection at 100 nM. 
Lipofectamine 200 were used as lipofection control. The nanovectors used to transfect BRAF 
gene were non-pegylated and pegylated DODAB:MO:DC-Chol (5:4:1 and 4:1:1). Gene expression 
levels normalized with GAPDH. 
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Figure 2. Physicochemical characterization of lipoplexes at different charge ratios. Z-average 
ŵeaŶ size ;ŶŵͿ ;AͿ; PolǇdispeƌsitǇ IŶdeǆ ;PdIͿ ;BͿ aŶd ɺ-potential (mV) (C) of DODAB/C:MO:DC-
Chol liposomes over 30 days. Data are presented as mean ± S.D. 
 
